

# Anthony E Lang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7769391/publications.pdf>

Version: 2024-02-01

977  
papers

116,309  
citations

172

154  
h-index

230

306  
g-index

1063  
all docs

1063  
docs citations

1063  
times ranked

52716  
citing authors

#	ARTICLE	IF	CITATIONS
1	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	3.9	4,796
2	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	3.9	4,389
3	Parkinson's disease. <i>Lancet, The</i> , 2015, 386, 896-912.	13.7	4,079
4	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17013.	30.5	3,048
5	Parkinson's Disease. <i>New England Journal of Medicine</i> , 1998, 339, 1044-1053.	27.0	1,876
6	Phenomenology and classification of dystonia: A consensus update. <i>Movement Disorders</i> , 2013, 28, 863-873.	3.9	1,754
7	Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1651-1661.	27.0	1,747
8	Levodopa and the Progression of Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2498-2508.	27.0	1,649
9	Deep-Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2001, 345, 956-963.	27.0	1,538
10	A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. <i>New England Journal of Medicine</i> , 2000, 342, 1484-1491.	27.0	1,467
11	Criteria for the diagnosis of corticobasal degeneration. <i>Neurology</i> , 2013, 80, 496-503.	1.1	1,445
12	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	3.9	1,402
13	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. <i>Lancet Neurology, The</i> , 2008, 7, 583-590.	10.2	1,340
14	Impulse Control Disorders in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 589-95.	4.5	1,244
15	Parkinson's Disease. <i>New England Journal of Medicine</i> , 1998, 339, 1130-1143.	27.0	1,147
16	Consensus statement on the diagnosis of multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 1999, 163, 94-98.	0.6	1,143
17	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.	3.9	1,097
18	Pharmacological Treatment of Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1670.	7.4	1,097

#	ARTICLE	IF	CITATIONS
19	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	3.9	1,033
20	Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. <i>Brain</i> , 2005, 128, 2240-2249.	7.6	963
21	FRONTAL LOBE DYSFUNCTION IN PARKINSON'S DISEASE. <i>Brain</i> , 1986, 109, 845-883.	7.6	919
22	Randomized controlled trial of intraputaminal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Annals of Neurology</i> , 2006, 59, 459-466.	5.3	890
23	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1268-1278.	27.0	830
24	Consensus statement on the diagnosis of multiple system atrophy. <i>Clinical Autonomic Research</i> , 1998, 8, 359-362.	2.5	823
25	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003, 54, 93-101.	5.3	820
26	Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes. <i>Movement Disorders</i> , 2006, 21, S290-S304.	3.9	811
27	Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. <i>Neurology</i> , 2003, 60, 69-73.	1.1	771
28	THE ANATOMICAL BASIS OF SYMPTOMATIC HEMIDYSTONIA. <i>Brain</i> , 1985, 108, 463-483.	7.6	666
29	Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. <i>Annals of Neurology</i> , 1998, 44, 622-628.	5.3	653
30	Gastrointestinal dysfunction in Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 625-639.	10.2	653
31	Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. <i>Brain</i> , 2002, 125, 1196-1209.	7.6	645
32	Effect of GPI pallidotomy on motor function in Parkinson's disease. <i>Lancet</i> , The, 1995, 346, 1383-1387.	13.7	620
33	Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. <i>Neurology</i> , 1998, 51, 850-855.	1.1	608
34	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	3.9	608
35	A Controlled Trial of Rasagiline in Early Parkinson Disease. <i>Archives of Neurology</i> , 2002, 59, 1937.	4.5	559
36	PROCEDURAL LEARNING AND NEOSTYRIAL DYSFUNCTION IN MAN. <i>Brain</i> , 1988, 111, 941-960.	7.6	546

#	ARTICLE	IF	CITATIONS
37	Tardive dystonia. <i>Neurology</i> , 1982, 32, 1335-1335.	1.1	534
38	Beta Oscillatory Activity in the Subthalamic Nucleus and Its Relation to Dopaminergic Response in Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2006, 96, 3248-3256.	1.8	520
39	Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 455.	7.4	509
40	Corticalâ€basal ganglionic degeneration. <i>Neurology</i> , 1990, 40, 1203-1203.	1.1	508
41	Highâ€frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. <i>Annals of Neurology</i> , 1997, 42, 292-299.	5.3	508
42	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. <i>Annals of Neurology</i> , 2003, 54, S15-S19.	5.3	496
43	Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. <i>Brain</i> , 2000, 123, 2091-2108.	7.6	488
44	Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. <i>Brain</i> , 2009, 132, 1376-1385.	7.6	475
45	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016, 31, 1272-1282.	3.9	464
46	A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. <i>Brain</i> , 2008, 131, 2720-2728.	7.6	460
47	Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. <i>JAMA Neurology</i> , 2018, 75, 1132.	9.0	455
48	Posteroventral Medial Pallidotomy in Advanced Parkinson's Disease. <i>New England Journal of Medicine</i> , 1997, 337, 1036-1043.	27.0	453
49	Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1044-53.	4.5	446
50	Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. <i>Neurology</i> , 2006, 67, 1254-1257.	1.1	416
51	Ten-Year Outcome of Subthalamic Stimulation in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 1550.	4.5	397
52	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. <i>Neurology</i> , 2001, 56, 1702-1706.	1.1	392
53	Longâ€term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 578-586.	3.9	382
54	Globus pallidus internus pallidotomy for generalized dystonia. <i>Movement Disorders</i> , 1997, 12, 865-870.	3.9	379

#	ARTICLE	IF	CITATIONS
55	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	3.9	379
56	Definition and classification of hyperkinetic movements in childhood. <i>Movement Disorders</i> , 2010, 25, 1538-1549.	3.9	374
57	Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2006, 66, 845-851.	1.1	371
58	Globus pallidus deep brain stimulation for generalized dystonia: Clinical and PET investigation. <i>Neurology</i> , 1999, 53, 871-871.	1.1	362
59	Impulse control disorders in parkinson disease: A multicenter caseâ€“control study. <i>Annals of Neurology</i> , 2011, 69, 986-996.	5.3	361
60	Practice parameter: Initiation of treatment for Parkinsonâ€™s disease: An evidence-based review. <i>Neurology</i> , 2002, 58, 11-17.	1.1	344
61	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDEâ€“PD study. <i>Annals of Neurology</i> , 2010, 68, 18-27.	5.3	330
62	Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. <i>Annals of Neurology</i> , 1996, 39, 37-45.	5.3	329
63	Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 1460.	4.5	326
64	Factors Associated With Dopaminergic Drugâ€“Related Pathological Gambling in Parkinson Disease. <i>Archives of Neurology</i> , 2007, 64, 212.	4.5	322
65	Prospective prevalence of pathologic gambling and medication association in Parkinson disease. <i>Neurology</i> , 2006, 66, 1750-1752.	1.1	316
66	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002, 50, 1268-1276.	1.1	314
67	Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. <i>Journal of Neurosurgery</i> , 2003, 99, 489-495.	1.6	306
68	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2009, 22, 430-436.	3.6	303
69	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology</i> , The, 2017, 16, 552-563.	10.2	303
70	Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. <i>Lancet Neurology</i> , The, 2004, 3, 309-316.	10.2	302
71	Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 716.	4.5	295
72	Utility of an objective dyskinesia rating scale for Parkinson's disease: Interâ€“and intrarater reliability assessment. <i>Movement Disorders</i> , 1994, 9, 390-394.	3.9	291

#	ARTICLE	IF	CITATIONS
73	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. <i>Lancet Neurology</i> , 2007, 6, 652-662.	10.2	290
74	Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. <i>Brain</i> , 2006, 129, 1059-1069.	7.6	286
75	Mutations in GNAL cause primary torsion dystonia. <i>Nature Genetics</i> , 2013, 45, 88-92.	21.4	281
76	Evolving basic, pathological and clinical concepts in PD. <i>Nature Reviews Neurology</i> , 2016, 12, 65-66.	10.1	279
77	Primary Dystonia Is More Responsive than Secondary Dystonia to Pallidal Interventions: Outcome after Pallidotomy or Pallidal Deep Brain Stimulation. <i>Neurosurgery</i> , 2004, 54, 613-621.	1.1	278
78	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. <i>Movement Disorders</i> , 2018, 33, 660-677.	3.9	275
79	Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. <i>Annals of Neurology</i> , 2002, 51, 604-612.	5.3	274
80	Contemporary assessment and pharmacotherapy of Tourette syndrome. <i>NeuroRx</i> , 2006, 3, 192-206.	6.0	273
81	Clinical Correlations With Lewy Body Pathology in <i>LRRK2</i> -Related Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 100.	9.0	272
82	How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. <i>Brain</i> , 2012, 135, 1860-1870.	7.6	270
83	Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. <i>Journal of Neurosurgery</i> , 2002, 97, 1152-1166.	1.6	267
84	A comparison of the mini mental state exam to the montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 297-299.	3.9	266
85	Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients. <i>NeuroReport</i> , 1994, 5, 1533-1537.	1.2	264
86	Long-Term Follow-up of Unilateral Pallidotomy in Advanced Parkinson's Disease. <i>New England Journal of Medicine</i> , 2000, 342, 1708-1714.	27.0	263
87	Effects of Apomorphine on Subthalamic Nucleus and Globus Pallidus Internus Neurons in Patients With Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2001, 86, 249-260.	1.8	261
88	Deep brain stimulation: Preoperative issues. <i>Movement Disorders</i> , 2006, 21, S171-S196.	3.9	260
89	Short and long latency afferent inhibition in Parkinson's disease. <i>Brain</i> , 2003, 126, 1883-1894.	7.6	258
90	Neuropsychological Outcome of GPi Pallidotomy and GPi or STN Deep Brain Stimulation in Parkinson's Disease. <i>Brain and Cognition</i> , 2000, 42, 324-347.	1.8	255

#	ARTICLE	IF	CITATIONS
91	Î±-Synuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , 2013, 73, 155-169.	5.3	255
92	Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation. <i>Neurology</i> , 1999, 53, 561-561.	1.1	252
93	Caffeine for treatment of Parkinson disease. <i>Neurology</i> , 2012, 79, 651-658.	1.1	252
94	Pallidal neuronal activity: Implications for models of dystonia. <i>Annals of Neurology</i> , 2003, 53, 480-488.	5.3	246
95	Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. <i>Movement Disorders</i> , 2006, 21, 1941-1946.	3.9	245
96	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 676-685.	10.2	245
97	Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. <i>Movement Disorders</i> , 2004, 19, 656-662.	3.9	240
98	Interface between tauopathies and synucleinopathies: A tale of two proteins. <i>Annals of Neurology</i> , 2006, 59, 449-458.	5.3	240
99	Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. <i>Nature Genetics</i> , 2015, 47, 579-581.	21.4	237
100	Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. <i>Annals of Neurology</i> , 2003, 54, 271-274.	5.3	233
101	Memory and learning in early Parkinson's disease: Evidence for a "frontal lobe syndrome". <i>Brain and Cognition</i> , 1990, 13, 211-232.	1.8	232
102	Apraxia in movement disorders. <i>Brain</i> , 2005, 128, 1480-1497.	7.6	228
103	Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. <i>Movement Disorders</i> , 2016, 31, 436-457.	3.9	228
104	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002, 50, 1268-1276.	1.1	227
105	Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. <i>Annals of Neurology</i> , 2016, 80, 674-685.	5.3	226
106	Stimulation of the subthalamic nucleus and impulsivity: Release your horses. <i>Annals of Neurology</i> , 2009, 66, 817-824.	5.3	225
107	Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018, 84, 797-811.	5.3	225
108	Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2019, 380, 315-324.	27.0	225

#	ARTICLE	IF	CITATIONS
109	Gene delivery of neurturin to putamen and substantia nigra in <scp>P</scp>arkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015, 78, 248-257.	5.3	224
110	Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. <i>Neurology</i> , 2007, 68, 457-459.	1.1	223
111	Practical guidelines for managing adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , 2015, 17, 599-609.	2.4	222
112	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	3.9	222
113	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007, 22, 2409-2417.	3.9	221
114	Distribution, type, and origin of Parkin mutations: Review and case studies. <i>Movement Disorders</i> , 2004, 19, 1146-1157.	3.9	219
115	Hemiballism: revisiting a classic disorder. <i>Lancet Neurology</i> , The, 2003, 2, 661-668.	10.2	217
116	Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. <i>Nature Medicine</i> , 1997, 3, 671-674.	30.7	216
117	Dementia as the most common presentation of cortical-basal ganglionic degeneration. <i>Neurology</i> , 1999, 53, 1969-1969.	1.1	214
118	Botulinum toxin for simple motor tics. <i>Neurology</i> , 2001, 56, 605-610.	1.1	208
119	Bilateral globus pallidus stimulation for Huntington's disease. <i>Annals of Neurology</i> , 2004, 56, 290-294.	5.3	207
120	The prion hypothesis in Parkinson's disease: Braak to the future. <i>Acta Neuropathologica Communications</i> , 2013, 1, 2.	5.2	205
121	Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. <i>Neurology</i> , 2003, 61, 1601-1604.	1.1	204
122	Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results. <i>Movement Disorders</i> , 2015, 30, 500-509.	3.9	199
123	The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. <i>Human Molecular Genetics</i> , 2004, 13, 3161-3170.	2.9	196
124	Identification and characterization of neurons with tremor-frequency activity in human globus pallidus. <i>Experimental Brain Research</i> , 1997, 113, 557-563.	1.5	195
125	Cortical and spinal abnormalities in psychogenic dystonia. <i>Annals of Neurology</i> , 2006, 59, 825-834.	5.3	195
126	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337.	1.1	194



#	ARTICLE	IF	CITATIONS
127	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology</i> , The, 2011, 10, 415-423.	10.2	192
128	Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: A functional MRI case study. <i>Movement Disorders</i> , 2003, 18, 1508-1516.	3.9	191
129	Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. <i>Neurology</i> , 2010, 75, 1711-1716.	1.1	191
130	Effects of apomorphine on globus pallidus neurons in parkinsonian patients. <i>Annals of Neurology</i> , 1997, 42, 767-775.	5.3	189
131	Striatal dopamine distribution in Parkinsonian patients during life. <i>Journal of the Neurological Sciences</i> , 1985, 69, 223-230.	0.6	188
132	Parkinsonian syndromes associated with hydrocephalus: Case reports, a review of the literature, and pathophysiological hypotheses. <i>Movement Disorders</i> , 1994, 9, 508-520.	3.9	188
133	<i>L</i> -DJ-1 (PARK7) mutations are less frequent than <i>Parkin</i> (PARK2) mutations in early-onset Parkinson disease. <i>Neurology</i> , 2004, 62, 389-394.	1.1	188
134	Disease-modifying strategies for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1442-1450.	3.9	188
135	Chorein detection for the diagnosis of chorea-acanthocytosis. <i>Annals of Neurology</i> , 2004, 56, 299-302.	5.3	186
136	Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1125-1132.	1.9	184
137	Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. <i>Movement Disorders</i> , 2002, 17, 303-312.	3.9	183
138	Parkinson's disease subtypes: lost in translation?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 409-415.	1.9	181
139	The "essentials" of essential palatal tremor: a reappraisal of the nosology. <i>Brain</i> , 2006, 129, 832-840.	7.6	180
140	Predicting Motor Decline and Disability in Parkinson Disease. <i>Archives of Neurology</i> , 2002, 59, 1724.	4.5	179
141	Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. <i>Neurology</i> , 2013, 80, 1698-1701.	1.1	178
142	PAINFUL PARKINSON'S DISEASE. <i>Lancet</i> , The, 1986, 327, 1366-1369.	13.7	177
143	Teaching tape for the motor section of the toronto western spasmodic torticollis scale. <i>Movement Disorders</i> , 1997, 12, 570-575.	3.9	177
144	Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. <i>Translational Neurodegeneration</i> , 2017, 6, 8.	8.0	177

#	ARTICLE	IF	CITATIONS
145	Predictors of Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease Treated With Older (Ergot) vs Newer (Nonergot) Dopamine Agonists. <i>Archives of Neurology</i> , 2004, 61, 97.	4.5	174
146	Overview of the Extranigral Aspects of Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 167-72.	4.5	172
147	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	3.9	171
148	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. <i>European Journal of Neurology</i> , 2009, 16, 297-309.	3.3	170
149	Bioinformatics-Based Identification of Expanded Repeats: A Non-reference Intronic Pentamer Expansion in RFC1 Causes CANVAS. <i>American Journal of Human Genetics</i> , 2019, 105, 151-165.	6.2	170
150	Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms. <i>Brain</i> , 2001, 124, 2105-2118.	7.6	168
151	Toward a redefinition of Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 54-60.	3.9	165
152	Multiple system atrophy—parkinsonism with slow progression and prolonged survival: A diagnostic catch. <i>Movement Disorders</i> , 2012, 27, 1186-1190.	3.9	164
153	Crossroads in GDNF therapy for Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 136-141.	3.9	163
154	Phenotype in parkinsonian and nonparkinsonian <i>LRRK2</i> G2019S mutation carriers. <i>Neurology</i> , 2011, 77, 325-333.	1.1	163
155	The Fragile X Premutation Presenting as Essential Tremor. <i>Archives of Neurology</i> , 2003, 60, 117.	4.5	162
156	Analysis of the PINK1 Gene in a Large Cohort of Cases With Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1898-904.	4.5	162
157	A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008, 23, 2194-2201.	3.9	162
158	PARKINSON'S DISEASE AND DEPRESSION. <i>Brain</i> , 1986, 109, 279-292.	7.6	161
159	<i>LRRK2</i> gene in Parkinson disease. <i>Neurology</i> , 2005, 65, 696-700.	1.1	160
160	Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease. <i>Neurology</i> , 1998, 51, 207-215.	1.1	157
161	Effects of subthalamic nucleus stimulation on motor cortex excitability in Parkinson's disease. <i>Neurology</i> , 2002, 58, 1665-1672.	1.1	155
162	Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. <i>Neurology</i> , 2007, 68, 1782-1789.	1.1	154

#	ARTICLE	IF	CITATIONS
163	Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. <i>Brain</i> , 1999, 122, 405-416.	7.6	153
164	The spectrum of levodopa-related fluctuations in Parkinson's disease. <i>Neurology</i> , 1993, 43, 1459-1459.	1.1	152
165	Neurophysiological effects of stimulation through electrodes in the human subthalamic nucleus. <i>Brain</i> , 1999, 122, 1919-1931.	7.6	152
166	Deep brain stimulation for Parkinson's disease: Patient selection and evaluation. <i>Movement Disorders</i> , 2002, 17, S94-S101.	3.9	150
167	Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. <i>Neurology</i> , 2014, 82, 1791-1797.	1.1	147
168	Frozen shoulder and other shoulder disturbances in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1989, 52, 63-66.	1.9	145
169	Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. <i>Movement Disorders</i> , 2006, 21, 1844-1850.	3.9	145
170	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017, 32, 319-324.	3.9	145
171	Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. <i>Neurology</i> , 1998, 50, 1015-1020.	1.1	144
172	Gut-brain axis and the spread of $\alpha$ -synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019, 34, 307-316.	3.9	144
173	Evidence for inter-generational instability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. <i>Human Molecular Genetics</i> , 1995, 4, 1137-1146.	2.9	143
174	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 119-126.	10.1	141
175	Myoclonic dystonia. <i>Neurology</i> , 1983, 33, 825-825.	1.1	141
176	A novel locus for inherited myoclonus-dystonia on 18p11. <i>Neurology</i> , 2002, 59, 1183-1186.	1.1	140
177	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009, 34, 2758-2766.	5.4	140
178	Premotor Parkinson's disease: Concepts and definitions. <i>Movement Disorders</i> , 2012, 27, 608-616.	3.9	140
179	Uncovering the role of the insula in non-motor symptoms of Parkinson's disease. <i>Brain</i> , 2014, 137, 2143-2154.	7.6	140
180	Hypoxic-ischemic damage of the basal ganglia case reports and a review of the literature. <i>Movement Disorders</i> , 1990, 5, 219-224.	3.9	139

#	ARTICLE	IF	CITATIONS
181	Survival in Parkinson disease. <i>Neurology</i> , 2005, 64, 87-93.	1.1	139
182	Myoclonus-dystonia: significance of large <i>SGCE</i> deletions. <i>Human Mutation</i> , 2008, 29, 331-332.	2.5	138
183	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. <i>Movement Disorders</i> , 2009, 24, 1366-1374.	3.9	138
184	Psychogenic Dystonia: a Review of 18 Cases. <i>Canadian Journal of Neurological Sciences</i> , 1995, 22, 136-143.	0.5	137
185	Progressive ataxia and palatal tremor (PAPT): Clinical and MRI assessment with review of palatal tremors. <i>Brain</i> , 2004, 127, 1252-1268.	7.6	134
186	The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. <i>Human Molecular Genetics</i> , 2001, 10, 1649-1656.	2.9	133
187	Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: A PET study of resting-state glucose metabolism. <i>Brain</i> , 2001, 124, 1601-1609.	7.6	133
188	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. <i>Annals of Neurology</i> , 2017, 82, 503-513.	5.3	133
189	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010, 68, 963-968.	5.3	132
190	Association Between Early-Onset Parkinson Disease and 22q11.2 Deletion Syndrome. <i>JAMA Neurology</i> , 2013, 70, 1359.	9.0	132
191	Patient perception of tics and other movement disorders. <i>Neurology</i> , 1991, 41, 223-223.	1.1	132
192	Mutations in <i>SLC20A2</i> are a major cause of familial idiopathic basal ganglia calcification. <i>Neurogenetics</i> , 2013, 14, 11-22.	1.4	131
193	Prediction of cognition in Parkinson's disease with a clinical genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , The, 2017, 16, 620-629.	10.2	131
194	The nonmotor symptoms of Parkinson's disease—An overview. <i>Movement Disorders</i> , 2010, 25, S123-30.	3.9	130
195	Colonic mucosal $\alpha$ -synuclein lacks specificity as a biomarker for Parkinson disease. <i>Neurology</i> , 2015, 84, 609-616.	1.1	130
196	Neuronal Firing Rates and Patterns in the Globus Pallidus Internus of Patients With Cervical Dystonia Differ From Those With Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2007, 98, 720-729.	1.8	129
197	A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials. <i>Movement Disorders</i> , 2011, 26, 775-783.	3.9	128
198	Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the <i>TUBB4</i> gene. <i>Annals of Neurology</i> , 2013, 73, 537-545.	5.3	128

#	ARTICLE	IF	CITATIONS
199	Potentials recorded at the scalp by stimulation near the human subthalamic nucleus. <i>Clinical Neurophysiology</i> , 2001, 112, 431-437.	1.5	127
200	Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. <i>Neurology</i> , 2004, 63, 2410-2412.	1.1	127
201	Unusual clinical presentations of cortical-basal ganglionic degeneration. <i>Annals of Neurology</i> , 1996, 40, 893-900.	5.3	126
202	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , The, 2013, 12, 514-524.	10.2	126
203	Psychogenic Parkinsonism. <i>Archives of Neurology</i> , 1995, 52, 802-810.	4.5	125
204	Gait abnormalities in psychogenic movement disorders. <i>Movement Disorders</i> , 2007, 22, 395-399.	3.9	125
205	Punding prevalence in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1179-1181.	3.9	125
206	The Nature and Time Course of Cortical Activation Following Subthalamic Stimulation in Parkinson's Disease. <i>Cerebral Cortex</i> , 2010, 20, 1926-1936.	2.9	125
207	From psychogenic movement disorder to functional movement disorder: It's time to change the name. <i>Movement Disorders</i> , 2014, 29, 849-852.	3.9	125
208	Antidepressant Treatment Outcomes of Psychogenic Movement Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1529-1534.	2.2	125
209	Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [ <sup>11</sup> C] FLB-457 and PET study. <i>Neurobiology of Disease</i> , 2012, 48, 519-525.	4.4	123
210	Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease With Modafinil. <i>Clinical Neuropharmacology</i> , 2002, 25, 111-114.	0.7	122
211	Predictors of deterioration in health-related quality of life in Parkinson's disease: Results from the DATATOP trial. <i>Movement Disorders</i> , 2008, 23, 653-659.	3.9	122
212	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , 2013, 28, 1838-1846.	3.9	122
213	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	3.9	121
214	Botulinum Toxin for Essential Tremor of the Voice With Multiple Anatomical Sites of Tremor: A Crossover Design Study of Unilateral Versus Bilateral Injection. <i>Laryngoscope</i> , 2000, 110, 1366-1374.	2.0	120
215	Î±-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. <i>Trends in Neurosciences</i> , 2016, 39, 750-762.	8.6	120
216	Posttraumatic movement disorders: A review. <i>Movement Disorders</i> , 1989, 4, 20-36.	3.9	119

#	ARTICLE	IF	CITATIONS
217	Large-scale replication and heterogeneity in Parkinson disease genetic loci. <i>Neurology</i> , 2012, 79, 659-667.	1.1	119
218	Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease. <i>Neurotherapeutics</i> , 2014, 11, 6-23.	4.4	119
219	Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. <i>Neuropsychiatry, Neuropsychology and Behavioral Neurology</i> , 2001, 14, 169-76.	0.4	118
220	Involvement of the cerebellothalamocortical pathway in Parkinson disease. <i>Annals of Neurology</i> , 2010, 68, 816-824.	5.3	117
221	Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. <i>Brain</i> , 2014, 137, 565-575.	7.6	116
222	Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology</i> , The, 2019, 18, 865-879.	10.2	116
223	Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1392-1397.	3.9	115
224	Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: Confirmation of 14q CAG expansion. <i>Annals of Neurology</i> , 1995, 38, 684-687.	5.3	114
225	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	3.9	114
226	Dystonia in progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 352-356.	1.9	113
227	Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. <i>Neurology</i> , 2003, 60, 917-922.	1.1	113
228	Placebo effect of medication cost in Parkinson disease. <i>Neurology</i> , 2015, 84, 794-802.	1.1	112
229	Intracranial Hypotension With Parkinsonism, Ataxia, and Bulbar Weakness. <i>Archives of Neurology</i> , 1999, 56, 869.	4.5	111
230	Involvement of human thalamus in the preparation of self-paced movement. <i>Brain</i> , 2004, 127, 2717-2731.	7.6	111
231	The progression of Parkinson disease. <i>Neurology</i> , 2007, 68, 948-952.	1.1	109
232	Phenotype-Specific Diagnosis of Functional (Psychogenic) Movement Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 32.	4.2	108
233	Functional correlates of pallidal stimulation for Parkinson's disease. <i>Annals of Neurology</i> , 2001, 49, 155-164.	5.3	107
234	Analysis of the glucocerebrosidase gene in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 367-370.	3.9	107

#	ARTICLE	IF	CITATIONS
235	Helicobacter pylori infection is associated with worse severity of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 221-225.	2.2	107
236	Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Movement Disorders, 2007, 22, 990-997.	3.9	106
237	Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurology, The, 2008, 7, 927-938.	10.2	106
238	Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. Annals of Neurology, 2009, 66, 110-114.	5.3	106
239	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2010, 25, 1077-1081.	3.9	106
240	PARKINSON'S DISEASE. Brain, 1987, 110, 35-51.	7.6	105
241	The treatment of dystonic tremor: a systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 759-769.	1.9	105
242	AAV1/2-induced overexpression of A53T- $\alpha$ -synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Acta Neuropathologica Communications, 2017, 5, 11.	5.2	105
243	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. Journal of Neuropathology and Experimental Neurology, 2007, 66, 251-257.	1.7	104
244	Impairments of speed and amplitude of movement in Parkinson's disease: A pilot study. Movement Disorders, 2009, 24, 1001-1008.	3.9	104
245	Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. Lancet Neurology, The, 2020, 19, 452-461.	10.2	104
246	Adult-onset subacute sclerosing panencephalitis: Case reports and review of the literature. Movement Disorders, 1997, 12, 342-353.	3.9	103
247	Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: Support for the existence of cognitive circuits in the human pallidum. Brain, 2000, 123, 746-758.	7.6	103
248	Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 130-135.	1.9	103
249	Disease modification and biomarker development in Parkinson disease. Neurology, 2020, 94, 481-494.	1.1	103
250	Palliative care for advanced Parkinson disease: An interdisciplinary clinic and new scale, the ESAS-PD. Parkinsonism and Related Disorders, 2012, 18, S6-S9.	2.2	102
251	Caffeine as symptomatic treatment for Parkinson disease (Caf $\alpha$ -PD). Neurology, 2017, 89, 1795-1803.	1.1	102
252	Subthalamic Nucleus Stimulation: Improvements in Outcome With Reprogramming. Archives of Neurology, 2006, 63, 1266-1272.	4.5	101

#	ARTICLE	IF	CITATIONS
253	An investigation of the effects of subthalamic nucleus stimulation on acoustic measures of voice. <i>Movement Disorders</i> , 2000, 15, 1132-1138.	3.9	100
254	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309942.	1.9	100
255	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. <i>Lancet Neurology</i> , The, 2016, 15, 954-966.	10.2	100
256	Probiotics for Constipation in Parkinson Disease. <i>Neurology</i> , 2021, 96, e772-e782.	1.1	100
257	Historical and Clinical Features of Psychogenic Tremor: a Review of 70 Cases. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, 190-195.	0.5	99
258	Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase Ila clinical studies: Keys to success and roads to failure. <i>Movement Disorders</i> , 2006, 21, 1578-1594.	3.9	99
259	Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: A [ <sup>15</sup> O] H <sub>2</sub> O PET study. <i>Human Brain Mapping</i> , 2009, 30, 3901-3909.	3.6	99
260	Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics. <i>Annals of Neurology</i> , 2021, 89, 546-559.	5.3	99
261	Psychogenic Movement Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2003, 30, S94-S100.	0.5	97
262	The cerebellothalamocortical pathway in essential tremor. <i>Neurology</i> , 2003, 60, 1985-1987.	1.1	97
263	Interhemispheric and ipsilateral connections in Parkinson's disease: Relation to mirror movements. <i>Movement Disorders</i> , 2007, 22, 813-821.	3.9	97
264	Mirror movements in parkinsonism: evaluation of a new clinical sign. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1355-1359.	1.9	96
265	Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. <i>Annals of Neurology</i> , 2004, 55, 761-765.	5.3	95
266	Manganese-Induced Parkinsonism Associated With Methcathinone (Ephedrone) Abuse. <i>Archives of Neurology</i> , 2007, 64, 886.	4.5	95
267	Characterization of REM-Sleep Associated Ponto-Geniculo-Occipital Waves in the Human Pons. <i>Sleep</i> , 2007, 30, 823-827.	1.1	95
268	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0138721.	2.5	95
269	Parietal Pick's disease mimicking cortical-basal ganglionic degeneration. <i>Neurology</i> , 1994, 44, 1436-1436.	1.1	95
270	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. <i>Journal of Medical Genetics</i> , 2012, 49, 721-726.	3.2	94



#	ARTICLE	IF	CITATIONS
271	The microbiomeâ€“gutâ€“brain axis in Parkinson disease â€“ from basic research to the clinic. <i>Nature Reviews Neurology</i> , 2022, 18, 476-495.	10.1	94
272	Levodopa-related motor complications-Phenomenology. <i>Movement Disorders</i> , 2008, 23, S509-S514.	3.9	93
273	Psychogenic facial movement disorders: Clinical features and associated conditions. <i>Movement Disorders</i> , 2012, 27, 1544-1551.	3.9	93
274	Stereotypies: A critical appraisal and suggestion of a clinically useful definition. <i>Movement Disorders</i> , 2012, 27, 179-185.	3.9	93
275	Saliency network and parahippocampal dopamine dysfunction in memoryâ€“impaired Parkinson disease. <i>Annals of Neurology</i> , 2015, 77, 269-280.	5.3	93
276	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	3.9	93
277	Extrastriatal dopaminergic dysfunction in tourette syndrome. <i>Annals of Neurology</i> , 2010, 67, 170-181.	5.3	92
278	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , 2015, 30, 150-159.	3.9	92
279	Orthostatic tremor arises from an oscillator in the posterior fossa. <i>Movement Disorders</i> , 2001, 16, 272-279.	3.9	91
280	The many faces of corticobasal degeneration. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S336-S340.	2.2	91
281	Integrated safety of levodopaâ€“carbidopa intestinal gel from prospective clinical trials. <i>Movement Disorders</i> , 2016, 31, 538-546.	3.9	91
282	Benign hereditary chorea: Clinical, genetic, and pathological findings. <i>Annals of Neurology</i> , 2003, 54, 244-247.	5.3	90
283	Ataxiaâ€“telangiectasia: A review of movement disorders, clinical features, and genotype correlations. <i>Movement Disorders</i> , 2018, 33, 1238-1247.	3.9	90
284	Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations. <i>Movement Disorders</i> , 2004, 19, 22-28.	3.9	89
285	Corticobasal Ganglionic Degeneration and Progressive Supranuclear Palsy Presenting with Cognitive Decline. <i>Brain Pathology</i> , 1998, 8, 355-365.	4.1	89
286	Investigation of C9orf72 in 4 Neurodegenerative Disorders. <i>Archives of Neurology</i> , 2012, 69, 1583.	4.5	89
287	Investing in the Future: Stimulation of the Medial Prefrontal Cortex Reduces Discounting of Delayed Rewards. <i>Neuropsychopharmacology</i> , 2015, 40, 546-553.	5.4	89
288	Parkinson's diseaseâ€“related fatigue: A case definition and recommendations for clinical research. <i>Movement Disorders</i> , 2016, 31, 625-631.	3.9	89

#	ARTICLE	IF	CITATIONS
289	Tics and functional tic-like movements. <i>Neurology</i> , 2019, 93, 750-758.	1.1	89
290	Impairment of motor cortex activation and deactivation in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2001, 112, 600-607.	1.5	88
291	Vascular Parkinsonism: Deconstructing a Syndrome. <i>Movement Disorders</i> , 2015, 30, 886-894.	3.9	88
292	Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. <i>Journal of Neurology</i> , 1999, 246, 111-115.	3.6	86
293	Mutation analysis of <i>CHCHD10</i> in different neurodegenerative diseases. <i>Brain</i> , 2015, 138, e380-e380.	7.6	86
294	Effects of internal globus pallidus stimulation on motor cortex excitability. <i>Neurology</i> , 2001, 56, 716-723.	1.1	85
295	Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?. <i>Movement Disorders</i> , 2008, 23, 1689-1695.	3.9	85
296	Inhibition of voluntary activity by thalamic stimulation in humans: Relevance for the control of tremor. <i>Movement Disorders</i> , 1997, 12, 727-737.	3.9	84
297	Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: A case report. <i>Movement Disorders</i> , 2004, 19, 969-972.	3.9	84
298	Chronic acquired hepatocerebral degeneration: Case reports and new insights. <i>Movement Disorders</i> , 1995, 10, 714-722.	3.9	83
299	Surgery for Parkinson Disease. <i>Archives of Neurology</i> , 2000, 57, 1118.	4.5	83
300	Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. <i>Nature Medicine</i> , 2010, 16, 1223-1226.	30.7	83
301	Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. <i>Brain</i> , 2011, 134, 2096-2105.	7.6	83
302	Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5164-E5173.	7.1	83
303	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009, 34, 2758-66.	5.4	83
304	New developments in understanding the etiology of Parkinson's disease and in its treatment. <i>Current Opinion in Neurobiology</i> , 1998, 8, 783-790.	4.2	82
305	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 546-548.	10.2	82
306	STIMULUS-SENSITIVE MYOCLONUS IN AKINETIC-RIGID SYNDROMES. <i>Brain</i> , 1992, 115, 1875-1888.	7.6	81

#	ARTICLE	IF	CITATIONS
307	Posttraumatic painful torticollis. <i>Movement Disorders</i> , 2003, 18, 1482-1491.	3.9	81
308	Tardive dyskinesia syndromes: current concepts. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S113-S117.	2.2	81
309	Olfactory dysfunction in familial parkinsonism. <i>Neurology</i> , 1997, 49, 1262-1267.	1.1	80
310	Dopaminergic transplantation for parkinson's disease: Current status and future prospects. <i>Annals of Neurology</i> , 2009, 66, 591-596.	5.3	80
311	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 926.	7.4	80
312	Homozygous inheritance of the Machado-Joseph disease gene. <i>Annals of Neurology</i> , 1994, 36, 443-447.	5.3	78
313	Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off-state. <i>Movement Disorders</i> , 1999, 14, 585-589.	3.9	78
314	Movement Disorders on YouTube â€” Caveat Spectator. <i>New England Journal of Medicine</i> , 2011, 365, 1160-1161.	27.0	77
315	Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 638-649.	1.9	77
316	Stimulation of the Subthalamic Nucleus in Parkinson's Disease Does Not Produce Striatal Dopamine Release. <i>Neurosurgery</i> , 2003, 53, 1095-1105.	1.1	76
317	Functional neurological disorders in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 566-571.	1.9	76
318	Pallidal Deep Brain Stimulation in Cervical Dystonia: Clinical Outcome in Four Cases. <i>Canadian Journal of Neurological Sciences</i> , 2004, 31, 328-332.	0.5	75
319	â€œUnder pressureâ€™: is there a link between orthostatic hypotension and cognitive impairment in Î±-synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1311-1321.	1.9	75
320	Psychogenic dyskinesias in patients with organic movement disorders. <i>Movement Disorders</i> , 1990, 5, 127-133.	3.9	74
321	Pallidal Stimulation in Parkinson's Disease Patients with a Prior Unilateral Pallidotomy. <i>Canadian Journal of Neurological Sciences</i> , 1998, 25, 300-305.	0.5	74
322	Alimentary, my dear Watson? The challenges of enteric Î±-synuclein as a Parkinson's disease biomarker. <i>Movement Disorders</i> , 2014, 29, 444-450.	3.9	74
323	Essential pitfalls in â€œessentialâ€ tremor. <i>Movement Disorders</i> , 2017, 32, 325-331.	3.9	74
324	Invited Article: Changing concepts in Parkinson disease. <i>Neurology</i> , 2008, 70, 1996-2003.	1.1	73

#	ARTICLE	IF	CITATIONS
325	Peroxisomal D-bifunctional protein deficiency. <i>Neurology</i> , 2014, 82, 963-968.	1.1	73
326	Clinical and neural responses to cognitive behavioral therapy for functional tremor. <i>Neurology</i> , 2019, 93, e1787-e1798.	1.1	73
327	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
328	Firing rates of pallidal neurons are similar in Huntingtonâ€™s and Parkinsonâ€™s disease patients. <i>Experimental Brain Research</i> , 2005, 166, 230-236.	1.5	72
329	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 196-202.	0.5	72
330	Cortical Degeneration in Progressive Supranuclear Palsy. A Comparison with Cortical-Basal Ganglionic Degeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 726-734.	1.7	72
331	Criteria for deep-brain stimulation in Parkinsonâ€™s disease: review and analysis. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1695-1705.	2.8	71
332	Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 58-64.	2.2	71
333	The Movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 724-726.	1.9	71
334	Dystonia and Parkinson's disease: What is the relationship?. <i>Neurobiology of Disease</i> , 2019, 132, 104462.	4.4	71
335	Subthalamic Nucleus Stimulation. <i>Archives of Neurology</i> , 2006, 63, 1266.	4.5	70
336	Fixing the broken system of genetic locus symbols. <i>Neurology</i> , 2012, 78, 1016-1024.	1.1	70
337	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , 2019, 8, 28.	8.0	70
338	Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. <i>Current Opinion in Neurology</i> , 2018, 31, 484-490.	3.6	69
339	Dopa Dose-Dependent Sexual Deviation. <i>British Journal of Psychiatry</i> , 1983, 142, 296-298.	2.8	68
340	A Double-Blind Trial of Clonazepam in Benign Essential Tremor. <i>Clinical Neuropharmacology</i> , 1984, 7, 83-88.	0.7	68
341	Impaired presynaptic inhibition in the motor cortex in Parkinson disease. <i>Neurology</i> , 2009, 72, 842-849.	1.1	68
342	Perampanel, an AMPA antagonist, found to have no benefit in reducing â€œoffâ€•time in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 284-288.	3.9	68

#	ARTICLE	IF	CITATIONS
343	Subthalamic nucleusâ€”deep brain stimulation for early motor complications in Parkinson's diseaseâ€”the EARLYSTIM trial: Early is not always better. <i>Movement Disorders</i> , 2014, 29, 1751-1756.	3.9	68
344	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. <i>Movement Disorders</i> , 2016, 31, 290-298.	3.9	68
345	SECONDARY TIC DISORDERS. <i>Neurologic Clinics</i> , 1997, 15, 309-331.	1.8	67
346	Timing of deep brain stimulation in Parkinson disease: A need for reappraisal?. <i>Annals of Neurology</i> , 2013, 73, 565-575.	5.3	67
347	Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with Î±-synucleinopathies. <i>Neurobiology of Disease</i> , 2015, 78, 162-171.	4.4	67
348	Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study. <i>NeuroImage: Clinical</i> , 2018, 17, 179-187.	2.7	67
349	Hemiballism in multiple sclerosis. <i>Movement Disorders</i> , 1988, 3, 88-94.	3.9	66
350	Phenotypic spectrum and sex effects in eleven myoclonusâ€”dystonia families with Î¼â€”sarcoglycan mutations. <i>Movement Disorders</i> , 2008, 23, 588-592.	3.9	66
351	Bilateral subthalamic stimulation in <i>Parkin</i> and <i>PINK1</i> parkinsonism. <i>Neurology</i> , 2008, 70, 1186-1191.	1.1	66
352	Thalamic deep brain stimulation activates the cerebellothalamocortical pathway. <i>Neurology</i> , 2004, 63, 907-909.	1.1	65
353	Involvement of the Basal Ganglia and Cerebellar Motor Pathways in the Preparation of Self-Initiated and Externally Triggered Movements in Humans. <i>Journal of Neuroscience</i> , 2007, 27, 6029-6036.	3.6	65
354	Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 33-42.	1.8	65
355	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , 2020, 11, 572976.	2.4	65
356	Pergolide in late-stage Parkinson disease. <i>Annals of Neurology</i> , 1982, 12, 243-247.	5.3	64
357	Acute onset dystonic camptocormia caused by lenticular lesions. <i>Movement Disorders</i> , 2001, 16, 177-180.	3.9	64
358	Dopamineâ€”agonists and impulsivity in Parkinson's disease: Impulsive choices vs. impulsive actions. <i>Human Brain Mapping</i> , 2014, 35, 2499-2506.	3.6	64
359	Cortical Plasticity Induction by Pairing Subthalamic Nucleus Deep-Brain Stimulation and Primary Motor Cortical Transcranial Magnetic Stimulation in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2016, 36, 396-404.	3.6	64
360	Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimerâ€™s Disease and Parkinsonâ€™s Disease Affect Caregiver Mood and Burden. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 120.	3.4	64

#	ARTICLE	IF	CITATIONS
361	Regional cerebral glucose metabolism in SLE chorea: Further evidence that striatal hypometabolism is not a correlate of chorea. <i>Movement Disorders</i> , 1987, 2, 201-210.	3.9	63
362	Alterations of striatal neurons in benign hereditary chorea. <i>Movement Disorders</i> , 2005, 20, 1353-1357.	3.9	63
363	Behavioral effects of levodopa. <i>Movement Disorders</i> , 2015, 30, 90-102.	3.9	63
364	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 102-106.	2.2	63
365	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , 2020, 10, 875-891.	2.8	63
366	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , 2021, 27, 1451-1457.	30.7	63
367	Deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, S168-S170.	3.9	62
368	Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson disease. <i>Neurology</i> , 2007, 68, 356-363.	1.1	62
369	Hereditary parkinsonism: Parkinson disease look-alikes? An algorithm for clinicians to <i>PARK</i> genes and beyond. <i>Movement Disorders</i> , 2009, 24, 2042-2058.	3.9	62
370	<i>ATP13A2</i> variants in early-onset Parkinson's disease patients and controls. <i>Movement Disorders</i> , 2009, 24, 2104-2111.	3.9	62
371	Striatonigral Degeneration: Iron Deposition in Putamen Correlates with the Slit-like Void Signal of Magnetic Resonance Imaging. <i>Canadian Journal of Neurological Sciences</i> , 1994, 21, 311-318.	0.5	61
372	Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study. <i>Neurology</i> , 2006, 66, 1941-1943.	1.1	61
373	Understanding disability in Tourette syndrome. <i>Developmental Medicine and Child Neurology</i> , 2009, 51, 468-472.	2.1	61
374	Response to clozapine in a clinically identifiable subtype of schizophrenia. <i>British Journal of Psychiatry</i> , 2015, 206, 484-491.	2.8	61
375	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinson's Disease</i> , 2016, 2, .	5.3	61
376	Common Myths in the Use of Levodopa in Parkinson Disease. <i>JAMA Neurology</i> , 2017, 74, 633.	9.0	60
377	Involvement of the human subthalamic nucleus in movement preparation. <i>Neurology</i> , 2003, 61, 1538-1545.	1.1	59
378	Sustained relief of dystonia following cessation of deep brain stimulation. <i>Movement Disorders</i> , 2007, 22, 1958-1962.	3.9	59

#	ARTICLE	IF	CITATIONS
379	Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 86-95.	3.9	59
380	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADYâ€PD III). <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 360-368.	3.7	59
381	[18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 440.	3.4	58
382	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. <i>Neurology</i> , 2021, 97, 942-957.	1.1	58
383	Motor neuron disease-inclusion dementia presenting as cortical-basal ganglionic degeneration. <i>Movement Disorders</i> , 1999, 14, 674-680.	3.9	57
384	Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020, 35, 1755-1764.	3.9	57
385	rCBF changes associated with PPN stimulation in a patient with Parkinson's disease: A PET study. <i>Movement Disorders</i> , 2008, 23, 1051-1054.	3.9	56
386	Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. <i>Neurology</i> , 2014, 82, 2250-2251.	1.1	56
387	Global investigation and meta-analysis of the C9orf72 (G <sub>4</sub> C <sub>2</sub> ) repeat in Parkinson disease. <i>Neurology</i> , 2014, 83, 1906-1913.	1.1	56
388	Single Pulse Stimulation of the Human Subthalamic Nucleus Facilitates the Motor Cortex at Short Intervals. <i>Journal of Neurophysiology</i> , 2004, 92, 1937-1943.	1.8	55
389	Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias. <i>Neurology</i> , 2007, 68, 704-705.	1.1	54
390	Characteristic head drops and axial extension in advanced choreaâ€acanthocytosis. <i>Movement Disorders</i> , 2010, 25, 1487-1491.	3.9	54
391	Launching the movement disorders society genetic mutation database (MDSGene). <i>Movement Disorders</i> , 2016, 31, 607-609.	3.9	54
392	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). <i>Journal of Alzheimer's Disease</i> , 2017, 59, 707-721.	2.6	54
393	Factors Predictive of the Need for Levodopa Therapy in Early, Untreated Parkinson's Disease. <i>Archives of Neurology</i> , 1995, 52, 565-570.	4.5	53
394	Neuropsychological and behavioral changes and weight gain after medial pallidotomy. <i>Annals of Neurology</i> , 1997, 41, 834-835.	5.3	53
395	Letters to the Editor. <i>Movement Disorders</i> , 1998, 13, 851-854.	3.9	53
396	Changes in cortical and pallidal oscillatory activity during the execution of a sensory trick in patients with cervical dystonia. <i>Experimental Neurology</i> , 2007, 204, 845-848.	4.1	53

#	ARTICLE	IF	CITATIONS
397	Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 259.	3.4	53
398	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. <i>Brain</i> , 2016, 139, 2050-2062.	7.6	53
399	Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 109-110.	2.2	53
400	When and how should treatment be started in Parkinson disease?. <i>Neurology</i> , 2009, 72, S39-43.	1.1	52
401	Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease. <i>Human Brain Mapping</i> , 2013, 34, 1591-1604.	3.6	52
402	Immediate Motor Effects of Stimulation through Electrodes Implanted in the Human Globus Pallidus. <i>Stereotactic and Functional Neurosurgery</i> , 1998, 70, 1-18.	1.5	51
403	Deep Brain Stimulator Electrodes Used for Lesioning: Proof of Principle. <i>Neurosurgery</i> , 2001, 49, 363-369.	1.1	51
404	MIXED LINEAGE KINASE INHIBITOR CEP-1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE. <i>Neurology</i> , 2008, 71, 462-463.	1.1	51
405	Caffeine consumption and risk of dyskinesia in <sc>CALM</sc>-PD. <i>Movement Disorders</i> , 2013, 28, 380-383.	3.9	51
406	Pallidal deep brain stimulation modulates cortical excitability and plasticity. <i>Annals of Neurology</i> , 2018, 83, 352-362.	5.3	51
407	Anticholinergics in Adult-Onset Focal Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1982, 9, 313-319.	0.5	50
408	Treatment of progressive supranuclear palsy and corticobasal degeneration. <i>Movement Disorders</i> , 2005, 20, S83-S91.	3.9	50
409	Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. <i>Journal of Neurosurgery</i> , 2005, 103, 246-251.	1.6	50
410	Benign hereditary chorea revisited: A journey to understanding. <i>Movement Disorders</i> , 2007, 22, 2297-2305.	3.9	50
411	Persistent Hemiballismus with Lesions Outside the Subthalamic Nucleus. <i>Canadian Journal of Neurological Sciences</i> , 1985, 12, 125-128.	0.5	49
412	Perioperative Problems in Parkinson's Disease and Their Management: Apomorphine with Rectal Domperidone. <i>Canadian Journal of Neurological Sciences</i> , 1996, 23, 198-203.	0.5	49
413	Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 639-645.	1.2	49
414	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force "An Update. <i>Movement Disorders</i> , 2022, 37, 905-935.	3.9	49



#	ARTICLE	IF	CITATIONS
415	Letters to the editor. <i>Movement Disorders</i> , 1990, 5, 352-355.	3.9	48
416	A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. <i>Movement Disorders</i> , 2009, 24, 2081-2090.	3.9	48
417	Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. <i>Movement Disorders</i> , 2016, 31, 1243-1247.	3.9	48
418	Unusual tremor syndromes: know in order to recognise. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1191-1203.	1.9	48
419	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3150-3160.	4.3	48
420	Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinson's Disease</i> , 2018, 8, S59-S64.	2.8	48
421	Botulinum Toxin Injections in the Treatment of Blepharospasm, Hemifacial Spasm, and Eyelid Fasciculations. <i>Canadian Journal of Neurological Sciences</i> , 1988, 15, 276-280.	0.5	47
422	Movement sequencing disorders in parkinson's disease. <i>International Journal of Neuroscience</i> , 1993, 73, 183-194.	1.6	47
423	Pallidotomy for Parkinson's Disease. <i>Neurosurgery Clinics of North America</i> , 1998, 9, 325-336.	1.7	47
424	Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 36, 67-75.	1.5	47
425	Long-term double-blind unilateral pedunculopontine area stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1570-1574.	3.9	47
426	Postanoxic symptomatic oscillatory myoclonus. <i>Neurology</i> , 1983, 33, 240-240.	1.1	47
427	Syringomyelic dystonia and athetosis. <i>Movement Disorders</i> , 1999, 14, 684-688.	3.9	46
428	Mutations in the $\mu$ sarcoglycan gene found to be uncommon in seven myoclonus-dystonia families. <i>Neurology</i> , 2003, 61, 244-246.	1.1	46
429	Subthalamic nucleus deep brain stimulation for parkinson's disease after successful pallidotomy: Clinical and electrophysiological observations. <i>Movement Disorders</i> , 2004, 19, 1209-1214.	3.9	46
430	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2005, 18, 399-404.	3.6	46
431	The spectrum of orolingual tremor: A proposed classification system. <i>Movement Disorders</i> , 2008, 23, 159-167.	3.9	46
432	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. <i>Lancet Neurology</i> , The, 2012, 11, 643-650.	10.2	46

#	ARTICLE	IF	CITATIONS
433	Associated movement disorders in orthostatic tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 725-729.	1.9	46
434	Levodopa challenge test: indications, protocol, and guide. Journal of Neurology, 2021, 268, 3135-3143.	3.6	46
435	Secondary dystonia. Advances in Neurology, 1988, 50, 9-33.	0.8	46
436	Afferents contributing to the exaggerated long latency reflex response to electrical stimulation in Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 1405-1410.	1.9	45
437	Posteroventral medial pallidotomy in Parkinson's disease. Journal of Neurology, 1999, 246, 1128-1141.	3.6	45
438	A writing device improves writing in primary writing tremor. Neurology, 2005, 64, 1648-1650.	1.1	45
439	Patient perception of dyskinesia in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1112-1115.	1.9	45
440	Acquired neurosyphilis presenting as movement disorders. Movement Disorders, 2012, 27, 690-695.	3.9	45
441	Another face of placebo: The lessebo effect in Parkinson disease. Neurology, 2014, 82, 1402-1409.	1.1	45
442	Minimal change multiple system atrophy: An aggressive variant?. Movement Disorders, 2015, 30, 960-967.	3.9	45
443	Altered gut microbiome and metabolome in patients with multiple system atrophy. Movement Disorders, 2018, 33, 174-176.	3.9	45
444	<i>Helicobacter pylori</i> Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial. Movement Disorders, 2020, 35, 2250-2260.	3.9	45
445	Alcohol and Parkinson disease. Annals of Neurology, 1982, 12, 254-256.	5.3	44
446	Familial dystonia and visual failure with striatal CT lucencies.. Journal of Neurology, Neurosurgery and Psychiatry, 1986, 49, 500-509.	1.9	44
447	Motor effects of stimulating the human cerebellar thalamus.. Journal of Physiology, 1995, 489, 287-298.	2.9	44
448	Motor Cortical Stimulation for Parkinsonism in Multiple System Atrophy. Archives of Neurology, 2003, 60, 1554.	4.5	44
449	Prenatal and Perinatal Morbidity in Children with Tourette Syndrome and Attention-Deficit Hyperactivity Disorder. Journal of Developmental and Behavioral Pediatrics, 2009, 30, 115-121.	1.1	44
450	Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study. Movement Disorders, 2011, 26, 2427-2431.	3.9	44

#	ARTICLE	IF	CITATIONS
451	What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 79-84.	1.8	44
452	Cortical basal ganglionic degeneration presenting with "progressive loss of speech output and orofacial dyspraxia".. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992, 55, 1101-1101.	1.9	43
453	Changes in cortical excitability with thalamic deep brain stimulation. <i>Neurology</i> , 2005, 64, 1913-1919.	1.1	43
454	Long-term subthalamic nucleus stimulation improves sensorimotor integration and proprioception. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1020-1028.	1.9	43
455	Abolishing the 1â€year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.	3.9	43
456	The Parkinson's disease eâ€diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	3.9	43
457	Presentation of Creutzfeldtâ€Jakob disease as acute corticobasal degeneration syndrome. <i>Movement Disorders</i> , 2004, 19, 948-949.	3.9	42
458	Electrophysiological features of myoclonusâ€dystonia. <i>Movement Disorders</i> , 2008, 23, 2055-2061.	3.9	42
459	Psychogenic movement disorders: Past developments, current status, and future directions. <i>Movement Disorders</i> , 2011, 26, 1175-1186.	3.9	42
460	Restless Genital Syndrome in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1559.	9.0	42
461	DEMENTIA PREVALENCE IN PARKINSON'S DISEASE. <i>Lancet, The</i> , 1985, 325, 1037.	13.7	41
462	Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. <i>Annals of Neurology</i> , 2000, 47, 369-373.	5.3	41
463	Editorial. <i>Movement Disorders</i> , 2002, 17, 1-2.	3.9	41
464	The proteasomal inhibition model of Parkinson's disease: â€œBoon or bustâ€?. <i>Annals of Neurology</i> , 2006, 60, 158-161.	5.3	41
465	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 329-336.	1.7	41
466	Refinement of the DYT15 locus in myoclonus dystonia. <i>Movement Disorders</i> , 2007, 22, 888-892.	3.9	41
467	Imaging changes associated with cognitive abnormalities in Parkinsonâ€™s disease. <i>Brain Structure and Function</i> , 2015, 220, 2249-2261.	2.3	41
468	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinsonâ€™s disease. <i>Brain</i> , 2017, 140, 1371-1383.	7.6	41

#	ARTICLE	IF	CITATIONS
469	Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade. <i>European Journal of Neurology</i> , 2020, 27, 975-984.	3.3	41
470	Treatment of Parkinson's disease with agents other than Levodopa and Dopamine Agonists: controversies and new approaches. <i>Canadian Journal of Neurological Sciences</i> , 1984, 11, 210-220.	0.5	40
471	Can the Lombard effect be used to improve low voice intensity in Parkinson's disease?. <i>International Journal of Language and Communication Disorders</i> , 1992, 27, 121-127.	1.5	40
472	Dose-induced penile erections in response to ropinirole therapy for Parkinson's disease. <i>Movement Disorders</i> , 1999, 14, 701-702.	3.9	40
473	Inherited myoclonus-dystonia: Evidence supporting genetic heterogeneity. <i>Movement Disorders</i> , 2001, 16, 106-110.	3.9	40
474	Corticobasal degeneration: Selected developments. <i>Movement Disorders</i> , 2003, 18, 51-56.	3.9	40
475	The curious case of phenocopies in families with genetic Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1793-1802.	3.9	40
476	Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 364-368.	1.9	40
477	Deficits in the Mimicry of Facial Expressions in Parkinson's Disease. <i>Frontiers in Psychology</i> , 2016, 7, 780.	2.1	40
478	Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. <i>The Journal of Otolaryngology</i> , 1993, 22, 171-5.	0.6	40
479	Reflex myoclonus in cortical-basal ganglionic degeneration involves a transcortical pathway. <i>Movement Disorders</i> , 1997, 12, 360-369.	3.9	39
480	Management of Parkinson's disease: An evidence-based review. <i>Movement Disorders</i> , 2002, 17, i-i.	3.9	39
481	Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments. <i>Movement Disorders</i> , 2013, 28, 1980-1986.	3.9	39
482	Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease. <i>Neurology</i> , 2015, 85, 425-432.	1.1	39
483	Deep Brain Stimulation in Rare Inherited Dystonias. <i>Brain Stimulation</i> , 2016, 9, 905-910.	1.6	39
484	Alcohol improves cerebellar learning deficit in myoclonus-dystonia: A clinical and electrophysiological investigation. <i>Annals of Neurology</i> , 2017, 82, 543-553.	5.3	39
485	Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. <i>Journal of Neurosurgery</i> , 1999, 90, 468-477.	1.6	38
486	Pardoprinox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. <i>Movement Disorders</i> , 2011, 26, 1464-1476.	3.9	38

#	ARTICLE	IF	CITATIONS
487	Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 53-57.	2.2	38
488	Parkinsonism in alcohol withdrawal: A follow-up study. <i>Movement Disorders</i> , 1990, 5, 36-39.	3.9	37
489	Effects of acute stimulation through contacts placed on the motor cortex for chronic stimulation. <i>Clinical Neurophysiology</i> , 2002, 113, 635-641.	1.5	37
490	Withdrawal akathisia: Case reports and a proposed classification of chronic akathisia. <i>Movement Disorders</i> , 2004, 9, 188-192.	3.9	37
491	Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: Differential effects on bradykinesia. <i>Movement Disorders</i> , 2007, 22, 328-333.	3.9	37
492	What is "essential" about essential tremor? A diagnostic placeholder. <i>Movement Disorders</i> , 2018, 33, 58-61.	3.9	37
493	Validation of the Movement Disorder Society Criteria for the Diagnosis of "Repeat Tauopathies". <i>Movement Disorders</i> , 2020, 35, 171-176.	3.9	37
494	Gestes antagonistes in psychogenic dystonia. <i>Movement Disorders</i> , 2004, 19, 331-332.	3.9	36
495	Dystonia as a presenting sign of spinocerebellar ataxia type 1. <i>Movement Disorders</i> , 2004, 19, 586-587.	3.9	36
496	Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. <i>Neurogenetics</i> , 2005, 6, 151-158.	1.4	36
497	Tremor retraining as therapeutic strategy in psychogenic (functional) tremor. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 647-650.	2.2	36
498	Mutation analysis of patients with neurodegenerative disorders using NeuroX array. <i>Neurobiology of Aging</i> , 2015, 36, 545.e9-545.e14.	3.1	36
499	Contribution of insula in Parkinson's disease: A quantitative meta-analysis study. <i>Human Brain Mapping</i> , 2016, 37, 1375-1392.	3.6	36
500	[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. <i>Brain Structure and Function</i> , 2018, 223, 589-595.	2.3	36
501	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018, 33, 1769-1776.	3.9	36
502	High Dose Anticholinergic Therapy in Adult Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1986, 13, 42-46.	0.5	35
503	"Signing tics"? Insights into the pathophysiology of symptoms in Tourette's syndrome. <i>Annals of Neurology</i> , 1993, 33, 212-215.	5.3	35
504	GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology</i> , The, 2006, 5, 200-202.	10.2	35

#	ARTICLE	IF	CITATIONS
505	Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 80-86.	2.2	35
506	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , 2018, 90, e2059-e2067.	1.1	35
507	Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1982, 45, 823-825.	1.9	33
508	Subdural motor cortex stimulation in Parkinson's disease does not modify movement-related rCBF pattern. <i>Movement Disorders</i> , 2007, 22, 2113-2116.	3.9	33
509	Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial. <i>Basal Ganglia</i> , 2011, 1, 91-95.	0.3	33
510	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 41-48.	2.2	33
511	Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies. <i>Neuroscience Letters</i> , 2018, 665, 18-21.	2.1	33
512	A Rostrocaudal Gradient for Aromatic Acid Decarboxylase in the Human Striatum. <i>Canadian Journal of Neurological Sciences</i> , 1987, 14, 444-447.	0.5	32
513	Natural History of Oppenheim's Dystonia (DYT1) in Israel. <i>Journal of Child Neurology</i> , 2003, 18, 325-330.	1.4	32
514	Double-blind study of pramipexole, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 738-746.	3.9	32
515	Pramipexole as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 370-376.	2.2	32
516	Movement disorders in patients with diabetes mellitus. <i>Journal of the Neurological Sciences</i> , 2012, 314, 5-11.	0.6	32
517	Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links <i>SCN1A</i> to early onset parkinsonian features. <i>Epilepsia</i> , 2017, 58, e44-e48.	5.1	32
518	Letters to the editor. <i>Movement Disorders</i> , 1995, 10, 527-529.	3.9	31
519	Phenocopies in a large GCH1 mutation positive family with dopa responsive dystonia: confusing the picture?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 801-804.	1.9	31
520	Genetic association study of PINK1 coding polymorphisms in Parkinson's disease. <i>Neuroscience Letters</i> , 2004, 372, 226-229.	2.1	31
521	Homozygous and heterozygous <i>PINK1</i> mutations: Considerations for diagnosis and care of Parkinson's disease patients. <i>Movement Disorders</i> , 2006, 21, 875-879.	3.9	31
522	Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. <i>Movement Disorders</i> , 2017, 32, 193-202.	3.9	31

#	ARTICLE	IF	CITATIONS
523	ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 512-520.	1.5	31
524	Alphamethylparatyrosine and Tetrabenazine in Movement Disorders. <i>Clinical Neuropharmacology</i> , 1982, 5, 375-388.	0.7	30
525	Progressive Dystonia With Bilateral Putaminal Hypodensities. <i>Archives of Neurology</i> , 1987, 44, 1184-1187.	4.5	30
526	Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: The spectrum of hemiparkinsonism-hemiatrophy syndrome. <i>Movement Disorders</i> , 1995, 10, 489-495.	3.9	30
527	Coexistence of tics and parkinsonism: Evidence for non-dopaminergic mechanisms in tic pathogenesis. <i>Neurology</i> , 1997, 49, 1699-1701.	1.1	30
528	The perioperative management of Parkinson's disease revisited. <i>Neurologic Clinics</i> , 2004, 22, 367-377.	1.8	30
529	Antidepressants in the Treatment of Psychosis With Comorbid Depression in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 90-92.	0.7	30
530	Development of a Non-Motor Fluctuation Assessment Instrument for Parkinson Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-13.	1.1	30
531	Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes. <i>Human Brain Mapping</i> , 2017, 38, 283-292.	3.6	30
532	Genomewide Association Studies of <i>LRRK2</i> Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 76-88.	5.3	30
533	Surgery for levodopa-induced dyskinesias. <i>Annals of Neurology</i> , 2000, 47, S193-9; discussion S199-202.	5.3	30
534	Pain in Gilles de la Tourette Syndrome and Related Tic Disorders. <i>Canadian Journal of Neurological Sciences</i> , 1989, 16, 439-441.	0.5	29
535	Pallidal and Thalamic Surgery for Parkinson's Disease. <i>Experimental Neurology</i> , 1997, 144, 35-40.	4.1	29
536	Neurodegenerative disease and the evolution of art: The effects of presumed corticobasal degeneration in a professional artist. <i>Movement Disorders</i> , 2003, 18, 294-302.	3.9	29
537	Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 893-903.	3.9	29
538	Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer's Disease, Parkinson's Disease, and Healthy Controls. <i>Frontiers in Neuroscience</i> , 2019, 13, 1259.	2.8	29
539	The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes. <i>Movement Disorders</i> , 2021, 36, 594-598.	3.9	28
540	Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. <i>Neurology</i> , 1996, 46, 1156-1157.	1.1	27

#	ARTICLE	IF	CITATIONS
541	Microelectrode Recordings Define the Ventral Posteromedial Pallidotomy Target. <i>Stereotactic and Functional Neurosurgery</i> , 1998, 71, 153-163.	1.5	27
542	Essential palatal tremor: Evidence of heterogeneity based on clinical features and response to sumatriptan. <i>Movement Disorders</i> , 1999, 14, 179-180.	3.9	27
543	Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease. <i>Movement Disorders</i> , 2005, 20, 371-377.	3.9	27
544	Large deletions account for an increasing number of mutations in <i>SGCE</i> . <i>Movement Disorders</i> , 2008, 23, 456-460.	3.9	27
545	Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson's Disease. <i>European Neurology</i> , 2009, 62, 40-48.	1.4	27
546	Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. <i>Movement Disorders</i> , 2012, 27, 326-327.	3.9	27
547	The Value of GRE, ADC and Routine MRI in Distinguishing Parkinsonian Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 389-402.	0.5	27
548	Integrated Therapy for Functional Movement Disorders: Time for a Change. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 169-174.	1.5	27
549	Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. <i>The Journal of Otolaryngology</i> , 1995, 24, 345-51.	0.6	27
550	Cardiac Valvulopathy Associated with Pergolide Use. <i>Canadian Journal of Neurological Sciences</i> , 2006, 33, 27-33.	0.5	26
551	Antipsychotic use in older adults with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 319-323.	3.9	26
552	'Don't delay, start today': delaying levodopa does not delay motor complications. <i>Brain</i> , 2014, 137, 2628-2630.	7.6	26
553	Repurposing drugs to treat L-DOPA-induced dyskinesia in Parkinson's disease. <i>Neuropharmacology</i> , 2019, 147, 11-27.	4.1	26
554	Using global team science to identify genetic parkinson's disease worldwide. <i>Annals of Neurology</i> , 2019, 86, 153-157.	5.3	26
555	Dopamine Agonists in the Treatment of Dystonia. <i>Clinical Neuropharmacology</i> , 1985, 8, 38-57.	0.7	25
556	Late adult onset chorea with typical pathology of Hallervorden-Spatz syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 392-395.	1.9	25
557	Isolated diaphragmatic tremor. <i>Neurology</i> , 2007, 69, 689-692.	1.1	25
558	Neuronal intranuclear inclusion disease: Two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1274-1279.	3.9	25



#	ARTICLE	IF	CITATIONS
559	Tongue control for swallowing in Parkinson's disease: Effects of age, rate, and stimulus consistency. <i>Movement Disorders</i> , 2011, 26, 1725-1729.	3.9	25
560	Neuropathological findings in chorea-acanthocytosis: new insights into mechanisms underlying parkinsonism and seizures. <i>Acta Neuropathologica</i> , 2014, 127, 613-615.	7.7	25
561	Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 222-225.	2.2	25
562	Unfreezing of gait in patients with Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 675-677.	10.2	25
563	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. <i>Neurology</i> , 2015, 85, 1283-1292.	1.1	25
564	Neurologic diagnostic criteria for functional neurologic disorders. <i>Handbook of Clinical Neurology</i> / Edited By PJ Vinken and G W Bruyn, 2016, 139, 193-212.	1.8	25
565	Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease. <i>Movement Disorders</i> , 2018, 33, 1700-1711.	3.9	25
566	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2146-2159.	1.2	25
567	ADCK3-related Coenzyme Q10 Deficiency: A Potentially Treatable Genetic Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 635-639.	1.5	25
568	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018, 125, 1373-1379.	2.8	25
569	Diagnostic importance of immunological markers in lymphoma involving the central nervous system. <i>Annals of Neurology</i> , 1984, 16, 668-672.	5.3	24
570	Waht is it? Case 1, 1990: Progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb. <i>Movement Disorders</i> , 1990, 5, 341-351.	3.9	24
571	Clinical Findings in a Large Family With a Parkin Ex3 <sup>Δ</sup> 40 Mutation. <i>Archives of Neurology</i> , 2004, 61, 701.	4.5	24
572	Impact of standard of care for psychosis in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1413-1415.	1.9	24
573	Reduced Intracortical and Interhemispheric Inhibitions in Corticobasal Syndrome. <i>Journal of Clinical Neurophysiology</i> , 2008, 25, 304-312.	1.7	24
574	Dystonia in complex regional pain syndrome type I. <i>Annals of Neurology</i> , 2010, 67, 412-414.	5.3	24
575	Pedunculopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 613-616.	1.9	24
576	Alternating Hemiplegia of Childhood as a New Presentation of Adenylate Cyclase 5-Mutation-Associated Disease: A Report of Two Cases. <i>Journal of Pediatrics</i> , 2017, 181, 306-308.e1.	1.8	24

#	ARTICLE	IF	CITATIONS
577	Corticobasal degeneration. <i>International Review of Neurobiology</i> , 2019, 149, 87-136.	2.0	24
578	Soft signs in movement disorders: friends or foes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 961-962.	1.9	24
579	Telemedicine in Movement Disorders: Leçons du COVID-19. <i>Movement Disorders</i> , 2020, 35, 1893-1896.	3.9	24
580	Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0153852.	2.5	24
581	What is it?. Case 1, 1995: Psychosis, dementia, chorea, ataxia, and supranuclear gaze dysfunction. <i>Movement Disorders</i> , 1995, 10, 257-262.	3.9	23
582	Timed tests in parkinson's disease evaluation1. <i>Movement Disorders</i> , 1997, 12, 127-128.	3.9	23
583	Pallidotomy for Tremor. <i>Movement Disorders</i> , 1998, 13, 107-110.	3.9	23
584	Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1801-1808.	3.9	23
585	Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. <i>Neurobiology of Aging</i> , 2011, 32, 2108.e1-2108.e5.	3.1	23
586	Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 968-971.	2.2	23
587	MRI signs of multiple system atrophy preceding the clinical diagnosis: the case for an imaging-supported probable MSA diagnostic category. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 443-444.	1.9	23
588	Linaclotide and Prucalopride for Management of Constipation in Patients with Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 218-220.	1.5	23
589	Myoclonus in complex regional pain syndrome. <i>Movement Disorders</i> , 2009, 24, 314-316.	3.9	22
590	Long-term effect of unilateral pallidotomy on levodopa-induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1496-1498.	3.9	22
591	Repetitive transcranial magnetic stimulation plus standardized suggestion of benefit for functional movement disorders: An open label case series. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 407-412.	2.2	22
592	Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. <i>Movement Disorders</i> , 2015, 30, 589-592.	3.9	22
593	Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 116-124.	1.5	22
594	Idiopathic Parkinson's disease: Revised Concepts of Cognitive and Affective Status. <i>Canadian Journal of Neurological Sciences</i> , 1988, 15, 106-113.	0.5	21

#	ARTICLE	IF	CITATIONS
595	Voluntary control and a wider clinical spectrum of essential palatal tremor. <i>Movement Disorders</i> , 2004, 19, 717-719.	3.9	21
596	Mirror movements in Parkinson's disease: effect of dopaminergic drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1194-1195.	1.9	21
597	Antidepressants and psychosis in Parkinson disease: a case series. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 601-604.	2.7	21
598	A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia. <i>Neurogenetics</i> , 2016, 17, 245-249.	1.4	21
599	Diagnostic delay in Parkinson's disease caused by PRKN mutations. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 217-220.	2.2	21
600	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 412-423.	1.9	21
601	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 267-282.	2.8	21
602	Subcognitive Processing in the Frontocaudate "Complex Loop". <i>Alzheimer Disease and Associated Disorders</i> , 1990, 4, 150-160.	1.3	20
603	Measuring motor complications in clinical trials for early Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 143-146.	1.9	20
604	Neuroprotection in Parkinson's disease: and now for something completely different?. <i>Lancet Neurology</i> , The, 2006, 5, 990-991.	10.2	20
605	Childhood Onset in Familial Prion Disease With a Novel Mutation in the PRNP Gene. <i>Archives of Neurology</i> , 2006, 63, 1016.	4.5	20
606	The G2019S <i>LRRK2</i> mutation in Brazilian patients with Parkinson's disease: Phenotype in monozygotic twins. <i>Movement Disorders</i> , 2008, 23, 290-294.	3.9	20
607	Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS4PD). <i>Movement Disorders</i> , 2010, 25, 1530-1537.	3.9	20
608	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , 2011, 26, 608-613.	3.9	20
609	Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. <i>Journal of Neurosurgery</i> , 2011, 114, 1428-1431.	1.6	20
610	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). <i>Quality of Life Research</i> , 2016, 25, 81-88.	3.1	20
611	Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration. <i>Movement Disorders</i> , 2021, 36, 1342-1352.	3.9	20
612	Dopamine agonists and antagonists in the treatment of idiopathic dystonia. <i>Advances in Neurology</i> , 1988, 50, 561-70.	0.8	20

#	ARTICLE	IF	CITATIONS
613	Flunarizine in Essential Tremor. <i>Clinical Neuropharmacology</i> , 1993, 16, 460-463.	0.7	19
614	Gestes antagonistes in the suppression of tics: "Tricks for tics". <i>Movement Disorders</i> , 1995, 10, 226-228.	3.9	19
615	Oxidative stress alters the regulatory control of p66Shc and Akt in PINK1 deficient cells. <i>Biochemical and Biophysical Research Communications</i> , 2010, 399, 331-335.	2.1	19
616	Wilson Disease: Canadian Perspectives on Presentation And Outcomes from an Adult Ambulatory Setting. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 333-339.	1.7	19
617	Implications of nocturnal symptoms towards the early diagnosis of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2014, 121, 49-57.	2.8	19
618	Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy. <i>Movement Disorders</i> , 2017, 32, 1465-1473.	3.9	19
619	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 1123.	2.4	19
620	Clinical phenomenology of tic disorders selected aspects. <i>Advances in Neurology</i> , 1992, 58, 25-32.	0.8	19
621	Case 1, 1994: Rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. <i>Movement Disorders</i> , 1994, 9, 358-366.	3.9	18
622	Atypical dopa responsive parkinsonism in a patient with megalencephaly, midbrain Lewy body disease, and some pathological features of Hallervorden-Spatz disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 61, 523-527.	1.9	18
623	Simultaneous repetitive movements following pallidotomy or subthalamic deep brain stimulation in patients with Parkinson's disease. <i>Experimental Brain Research</i> , 2002, 147, 322-331.	1.5	18
624	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. <i>Movement Disorders</i> , 2011, 26, 1348-1352.	3.9	18
625	Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 610-614.	3.9	18
626	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 503-510.	2.8	18
627	Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 105-118.	2.6	18
628	Parkinson's Disease, NOTCH3 Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020, 35, 2090-2095.	3.9	18
629	Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. , 2017, 8, 261.		18
630	Clinical diagnostic criteria. <i>Advances in Neurology</i> , 2000, 82, 29-34.	0.8	18

#	ARTICLE	IF	CITATIONS
631	Coexistence of Idiopathic Parkinson's Disease and Creutzfeldt-Jakob Disease. Canadian Journal of Neurological Sciences, 1985, 12, 272-273.	0.5	17
632	Association between familial tremor and Parkinson's disease. Annals of Neurology, 1986, 19, 306-306.	5.3	17
633	Pallidotomy Increases Cortical Inhibition in Parkinson's Disease. Canadian Journal of Neurological Sciences, 1997, 24, 133-136.	0.5	17
634	Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. Movement Disorders, 2003, 18, 942-948.	3.9	17
635	Severe evening dyskinesias in advanced Parkinson's disease: Clinical description, relation to plasma levodopa, and treatment. Movement Disorders, 2004, 9, 173-177.	3.9	17
636	Orthostatic tremor in progressive supranuclear palsy. Movement Disorders, 2007, 22, 1192-1194.	3.9	17
637	Initiating dopaminergic treatment in Parkinson's disease. Lancet, The, 2014, 384, 1164-1166.	13.7	17
638	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. Parkinsonism and Related Disorders, 2014, 20, 915-918.	2.2	17
639	Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [11 C]raclopride positron emission tomography imaging study. Human Brain Mapping, 2015, 36, 2592-2601.	3.6	17
640	Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease. Journal of Visualized Experiments, 2018, , .	0.3	17
641	&lt;p&gt;Orthostatic hypotension and dementia incidence: links and implications&lt;/p&gt;. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2181-2194.	2.2	17
642	Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?. Movement Disorders, 2021, 36, 1483-1484.	3.9	17
643	Anticholinergic Drugs and Amantadine in the Treatment of Parkinson's Disease. Handbook of Experimental Pharmacology, 1989, , 307-323.	1.8	17
644	Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease. PLoS ONE, 2017, 12, e0173944.	2.5	17
645	Deep Bayesian networks for uncertainty estimation and adversarial resistance of white matter hyperintensity segmentation. Human Brain Mapping, 2022, 43, 2089-2108.	3.6	17
646	Idiopathic generalized myokymia (Isaacs' syndrome) with hand posturing resembling dystonia. Movement Disorders, 1996, 11, 448-449.	3.9	16
647	Reversible dissociation of sensitivity to dynamic stimuli in Parkinson's disease: Is magnocellular function essential to reading motion-defined letters?. Vision Research, 1997, 37, 3531-3534.	1.4	16
648	Amoxapine Shows an Antipsychotic Effect but Worsens Motor Function in Patients with Parkinson's Disease and Psychosis. Clinical Neuropharmacology, 2001, 24, 242-244.	0.7	16

#	ARTICLE	IF	CITATIONS
649	Role of SCA2 mutations in early- and late-onset dopa-responsive parkinsonism. <i>Annals of Neurology</i> , 2002, 52, 257-258.	5.3	16
650	Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 985-993.	2.8	16
651	A case of a psychogenic "jumpy stump". <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1101-1101.	1.9	16
652	Diagnosing psychogenic movement disorders— which criteria should be used in clinical practice?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 134-135.	2.5	16
653	VITAMINS AND ENTACAPONE IN LEVODOPA-INDUCED HYPERHOMOCYSTEINEMIA: A RANDOMIZED CONTROLLED STUDY. <i>Neurology</i> , 2007, 68, 1440-1441.	1.1	16
654	Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation-dependent probe amplification. <i>Movement Disorders</i> , 2007, 22, 1708-1714.	3.9	16
655	The psychogenic toe signs. <i>Neurology</i> , 2011, 77, 508-509.	1.1	16
656	Clinical heterogeneity in Progressive Supranuclear Palsy: Challenges to diagnosis, pathogenesis and future therapies. <i>Movement Disorders</i> , 2014, 29, 1707-1709.	3.9	16
657	Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2016, 38, 217.e7-217.e8.	3.1	16
658	Movement disorders in non-encephalopathic Hashimoto's thyroiditis. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 141-142.	2.2	16
659	Pharmacology of cranial dystonia. <i>Neurology</i> , 1983, 33, 1100-1100.	1.1	16
660	Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. <i>Cmaj</i> , 1988, 139, 837-44.	2.0	16
661	Lithium and parkinsonism. <i>Annals of Neurology</i> , 1984, 15, 214-214.	5.3	15
662	A Major Locus for Myoclonus-Dystonia Maps to Chromosome 7q in Eight Families*. <i>American Journal of Human Genetics</i> , 2000, 67, 1314-1319.	6.2	15
663	A new sensitive imaging biomarker for Parkinson disease?. <i>Neurology</i> , 2009, 72, 1374-1375.	1.1	15
664	Expanding the phenomenology of benign hereditary chorea: Evolution from chorea to myoclonus and dystonia. <i>Movement Disorders</i> , 2011, 26, 2296-2297.	3.9	15
665	The pill questionnaire in a nondemented Parkinson's disease population. <i>Movement Disorders</i> , 2012, 27, 1308-1311.	3.9	15
666	Designing Clinical Trials for Dystonia. <i>Neurotherapeutics</i> , 2014, 11, 117-127.	4.4	15

#	ARTICLE	IF	CITATIONS
667	The role of mutations in COL6A3 in isolated dystonia. <i>Journal of Neurology</i> , 2016, 263, 730-734.	3.6	15
668	Paroxysmal Asymmetric Dystonic Arm Posturing—A Less Recognized but Characteristic Manifestation of ATP1A3-related disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 312-315.	1.5	15
669	Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 25-27.	2.2	15
670	Microelectrode recording-guided posteroventral pallidotomy in patients with Parkinson's disease. <i>Advances in Neurology</i> , 1997, 74, 167-74.	0.8	15
671	Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. <i>Alzheimer's and Dementia</i> , 2023, 19, 226-243.	0.8	15
672	Subthalamic DBS replaces levodopa in Parkinson's disease. <i>Neurology</i> , 2002, 59, 1293-1294.	1.1	14
673	Drug-induced cranial myoclonus. <i>Movement Disorders</i> , 2010, 25, 2264-2265.	3.9	14
674	A case of neurosyphilis presenting with myoclonus, cerebellar ataxia, and speech disturbance. <i>Movement Disorders</i> , 2012, 27, 794-794.	3.9	14
675	Clinicopathological review of pallidonigroluysian atrophy. <i>Movement Disorders</i> , 2013, 28, 274-281.	3.9	14
676	Extensive intracranial calcifications in a patient with a novel polymerase gamma-1 mutation. <i>Neurology</i> , 2013, 81, 197-198.	1.1	14
677	A practical approach to remote longitudinal follow-up of Parkinson's disease: The FOUND study. <i>Movement Disorders</i> , 2014, 29, 743-749.	3.9	14
678	Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 71.	6.2	14
679	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 67-69.	1.5	14
680	Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EARly Parkinson's disease: the LEAP-study. <i>BMC Neurology</i> , 2015, 15, 236.	1.8	14
681	Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway. <i>Neurobiology of Disease</i> , 2019, 124, 176-182.	4.4	14
682	The evidence for multidisciplinary care in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 539-549.	2.8	14
683	Improved Segmentation of the Intracranial and Ventricular Volumes in Populations with Cerebrovascular Lesions and Atrophy Using 3D CNNs. <i>Neuroinformatics</i> , 2021, 19, 597-618.	2.8	14
684	Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , 2021, 6, 80.	3.8	14

#	ARTICLE	IF	CITATIONS
685	Positron tomography in dystonia. <i>Advances in Neurology</i> , 1988, 50, 249-53.	0.8	14
686	Surgical treatment of dystonia. <i>Advances in Neurology</i> , 1998, 78, 185-98.	0.8	14
687	GDNF in Parkinson's disease: The perils of post-hoc power. <i>Journal of Neuroscience Methods</i> , 2007, 163, 193-196.	2.5	13
688	Functional/psychogenic movement disorders: Do we know what they are?. <i>Movement Disorders</i> , 2014, 29, 1696-1697.	3.9	13
689	Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 361-367.	1.8	13
690	Movement Disorders and Renal Diseases. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 763-779.	1.5	13
691	Movement Disorders Due to Selective Basal Ganglia Lesions with Uremia. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 350-365.	0.5	13
692	Clinical Differences Between Metoclopramide- and Antipsychotic-Induced Tardive Dyskinesias. <i>Canadian Journal of Neurological Sciences</i> , 1990, 17, 137-139.	0.5	12
693	Acute effect of transcutaneous electrical nerve stimulation on tremor. <i>Movement Disorders</i> , 2003, 18, 191-194.	3.9	12
694	Pure cerebello-olivary degeneration of Marie, Foix, and Alajouanine presenting with progressive cerebellar ataxia, cognitive decline, and chorea. <i>Movement Disorders</i> , 2003, 18, 1550-1554.	3.9	12
695	Subthalamic Stimulation for Parkinson's Disease "Living Better Electrically?". <i>New England Journal of Medicine</i> , 2003, 349, 1888-1891.	27.0	12
696	Does severity of Parkinson's disease vary according to season?. <i>Movement Disorders</i> , 2005, 20, 476-479.	3.9	12
697	Translational Research in Neurology and Neuroscience 2011. <i>Archives of Neurology</i> , 2011, 68, 709-16.	4.5	12
698	Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , 2018, 33, 960-965.	3.9	12
699	Sleep-related motor and behavioral disorders: Recent advances and new entities. <i>Movement Disorders</i> , 2018, 33, 1042-1055.	3.9	12
700	Remoxipride in the Treatment of Levodopa-Induced Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 395-399.	1.4	12
701	Combining Skin $\alpha$ -Synuclein Real-time Quaking-induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 648-650.	3.9	12
702	$\alpha$ -Synuclein molecular behavior and nigral proteomic profiling distinguish subtypes of Lewy body disorders. <i>Acta Neuropathologica</i> , 2022, 144, 167-185.	7.7	12



#	ARTICLE	IF	CITATIONS
703	Levodopa dose-related fluctuations in presumed olivopontocerebellar atrophy. <i>Movement Disorders</i> , 1986, 1, 93-102.	3.9	11
704	Update on Dopamine Agonists in Parkinson's Disease: "Beyond Bromocriptine". <i>Canadian Journal of Neurological Sciences</i> , 1987, 14, 474-482.	0.5	11
705	Tizanidine in Cranial Dystonia. <i>Clinical Neuropharmacology</i> , 1992, 15, 142-147.	0.7	11
706	Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review. <i>Neurology</i> , 2002, 59, 1292-1292.	1.1	11
707	Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. <i>Movement Disorders</i> , 2006, 21, 2251-2254.	3.9	11
708	Is there seasonal variation in risk of Parkinson's disease?. <i>Movement Disorders</i> , 2007, 22, 1097-1101.	3.9	11
709	Reversible dopamine agonist induced anterocollis in a multiple system atrophy patient. <i>Movement Disorders</i> , 2007, 22, 2292-2293.	3.9	11
710	Pergolide Associated Cardiac Valvulopathy Based on Ontario Administrative Data. <i>Canadian Journal of Neurological Sciences</i> , 2008, 35, 173-178.	0.5	11
711	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. <i>Movement Disorders</i> , 2009, 24, 2370-2378.	3.9	11
712	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 43, 151-156.	4.8	11
713	Dancing Dorsal Quadrilaterals. <i>JAMA Neurology</i> , 2019, 76, 351.	9.0	11
714	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 121-126.	2.2	11
715	Parkinson's Disease and COVID-19: Do We Need to Be More Patient?. <i>Movement Disorders</i> , 2021, 36, 277-277.	3.9	11
716	Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2419-2425.	3.9	11
717	MRI-visible perivascular space volumes, sleep duration and daytime dysfunction in adults with cerebrovascular disease. <i>Sleep Medicine</i> , 2021, 83, 83-88.	1.6	11
718	A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0178982.	2.5	11
719	Small and Large Magnetic Resonance Imaging "Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. <i>Movement Disorders</i> , 2022, 37, 1304-1309.	3.9	11
720	Cortical reflex myoclonus studied with cortical electrodes. <i>Clinical Neurophysiology</i> , 1999, 110, 1521-1530.	1.5	10

#	ARTICLE	IF	CITATIONS
721	Neuronal activity in the globus pallidus of multiple system atrophy patients. <i>Movement Disorders</i> , 2004, 19, 1485-1492.	3.9	10
722	Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. <i>Journal of Human Genetics</i> , 2011, 56, 671-675.	2.3	10
723	Voxel-Based Imaging of Translocator Protein 18Kda (TSPO) in High-Resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 348-350.	4.3	10
724	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 184-187.	1.5	10
725	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinson's Disease</i> , 2018, 8, 131-139.	2.8	10
726	Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Clinical Autonomic Research</i> , 2019, 29, 603-614.	2.5	10
727	Opsoclonus-myoclonus-encephalopathy induced by cefepime. <i>Journal of the Neurological Sciences</i> , 2019, 396, 33-35.	0.6	10
728	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 127-132.	2.2	10
729	Diagnosing functional neurological disorder: seeing the whole picture. <i>CNS Spectrums</i> , 2021, 26, 593-600.	1.2	10
730	Medial pallidotomy in late-stage Parkinson's disease and striatonigral degeneration. <i>Advances in Neurology</i> , 1997, 74, 199-211.	0.8	10
731	Spasmodic Dysphonia in Gilles de la Tourette's Disease. <i>Archives of Neurology</i> , 1983, 40, 51-52.	4.5	9
732	Sporadic case of dentatorubral pallidoluysian atrophy with no CAG repeat expansion and no intranuclear inclusions. <i>Movement Disorders</i> , 2004, 19, 580-583.	3.9	9
733	Rasagiline-induced spontaneous ejaculation. <i>Movement Disorders</i> , 2009, 24, 2160-2161.	3.9	9
734	Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy. <i>Experimental Brain Research</i> , 2010, 206, 1-13.	1.5	9
735	The grasp reflex: A symptom in need of treatment. <i>Movement Disorders</i> , 2010, 25, 2479-2485.	3.9	9
736	LRRK2 and Parkin mutations in a family with parkinsonism—Lack of genotype-phenotype correlation. <i>Neurobiology of Aging</i> , 2010, 31, 721-722.	3.1	9
737	Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. <i>Neurology</i> , 2012, 78, 838-838.	1.1	9
738	Genome-wide variant by serum urate interaction in Parkinson's disease. <i>Annals of Neurology</i> , 2015, 78, 731-741.	5.3	9

#	ARTICLE	IF	CITATIONS
739	A case cluster of variant Creutzfeldt-Jakob disease linked to the Kingdom of Saudi Arabia. <i>Brain</i> , 2016, 139, 2609-2616.	7.6	9
740	Basal ganglia calcification in a case of PKAN. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 98-99.	2.2	9
741	Reply to: "A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders". <i>Movement Disorders</i> , 2020, 35, 1903-1904.	3.9	9
742	DYT-TUBB4A (DYT4 Dystonia). <i>Neurology</i> , 2021, 96, e1887-e1897.	1.1	9
743	Proprioceptive recalibration following implicit visuomotor adaptation is preserved in Parkinson's disease. <i>Experimental Brain Research</i> , 2021, 239, 1551-1565.	1.5	9
744	Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. <i>BMC Neurology</i> , 2021, 21, 459.	1.8	9
745	A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. <i>Movement Disorders</i> , 2022, 37, 1265-1271.	3.9	9
746	Long latency between the onset of motor and vocal tics in Tourette's syndrome. <i>Annals of Neurology</i> , 1983, 14, 693-694.	5.3	8
747	Stiff-Person Syndrome. <i>Canadian Journal of Neurological Sciences</i> , 1992, 19, 383-388.	0.5	8
748	Farewell from the outgoing editors. <i>Movement Disorders</i> , 2004, 19, 2-2.	3.9	8
749	Insights into brain function through the examination of art: the influence of neurodegenerative diseases. <i>NeuroReport</i> , 2004, 15, 933-937.	1.2	8
750	Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 961-962.	3.9	8
751	Successful treatment of functional palatal tremor: Insights into pathogenesis and management. <i>Movement Disorders</i> , 2015, 30, 875-876.	3.9	8
752	Paroxysmal Hemiballism/Hemichorea Resulting from Transient Ischemic Attacks. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 303-305.	1.5	8
753	Oculogyric crises in PLA2G6 associated neurodegeneration. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 111-112.	2.2	8
754	Successful spinal cord stimulation for severe medication-refractory restless legs syndrome. <i>Movement Disorders</i> , 2019, 34, 585-586.	3.9	8
755	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 200-203.	2.2	8
756	The retina as a window to the basal ganglia: Systematic review of the potential link between retinopathy and hyperkinetic disorders in diabetes. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 194-198.	2.2	8

#	ARTICLE	IF	CITATIONS
757	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021, 105, 378.e1-378.e9.	3.1	8
758	The Effects of Pallidotomy on Parkinson's Disease: Study Design and Assessment Techniques. <i>Acta Neurochirurgica Supplementum</i> , 1997, 68, 24-28.	1.0	8
759	Parkinsonian Tremor. <i>Neurological Disease and Therapy</i> , 2005, , 195-220.	0.0	8
760	Patterns of Mixed Pathologies in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 595-607.	2.6	8
761	Protracted course progressive supranuclear palsy. <i>European Journal of Neurology</i> , 2022, 29, 2220-2231.	3.3	8
762	Manipulating the dopaminergic system in Parkinson's disease. , 1987, 32, 51-76.		7
763	“Weight-holding tremor”: An unusual task-specific form of essential tremor?. <i>Movement Disorders</i> , 1995, 10, 228-229.	3.9	7
764	Letters to the editor. <i>Movement Disorders</i> , 1995, 10, 235-237.	3.9	7
765	Dopa-responsive dystonia presenting with prominent isolated bilateral resting leg tremor: Evidence for a role of parkin?. <i>Movement Disorders</i> , 2003, 18, 1070-1072.	3.9	7
766	FIXED DYSTONIA UNRESPONSIVE TO PALLIDAL STIMULATION IMPROVED BY MOTOR CORTEX STIMULATION. <i>Neurology</i> , 2007, 69, 1062-1063.	1.1	7
767	Early-onset tardive dyskinesia in a neuroleptic-naïve patient exposed to low-dose quetiapine. <i>Movement Disorders</i> , 2011, 26, 2297-2298.	3.9	7
768	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. <i>Genetics in Medicine</i> , 2014, 16, 644-645.	2.4	7
769	Pantothenate kinase-associated neurodegeneration mimicking Tourette syndrome: a case report and review of the literature. <i>Neurological Sciences</i> , 2018, 39, 1797-1800.	1.9	7
770	Genetic Variation in the Ontario Neurodegenerative Disease Research Initiative. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 491-498.	0.5	7
771	The clinical significance of lower limb tremors. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 165-171.	2.2	7
772	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 138-145.	2.2	7
773	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. <i>Frontiers in Neurology</i> , 2020, 11, 574.	2.4	7
774	Primary brain calcification due to a homozygous MYORG mutation causing isolated paroxysmal kinesigenic dyskinesia. <i>Brain</i> , 2020, 143, e36-e36.	7.6	7

#	ARTICLE	IF	CITATIONS
775	Movement Disorders Associated with Hypogonadism. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 997-1011.	1.5	7
776	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7292.	4.1	7
777	Posteroventral medial pallidotomy in advanced Parkinson's disease. <i>Advances in Neurology</i> , 1999, 80, 575-83.	0.8	7
778	Myoclonus in parkinsonian disorders. <i>Advances in Neurology</i> , 2002, 89, 77-83.	0.8	7
779	Focal paroxysmal kinesigenic choreoathetosis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1984, 47, 1057-1058.	1.9	6
780	Dopa-responsive parkinsonism with normal 6[18F]-fluorodopa positron emission tomography scans. <i>Annals of Neurology</i> , 1990, 28, 592-593.	5.3	6
781	Motor and non-motor fluctuations. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2007, 84, 157-184.	1.8	6
782	Alien hand syndrome and dystonia in a pediatric patient. <i>Movement Disorders</i> , 2009, 24, 1557-1559.	3.9	6
783	A Survey on the Impact of the Menstrual Cycle on Movement Disorders Severity. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 478-481.	0.5	6
784	Clinical Vignettes in Parkinson's Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours. <i>International Journal of Neuroscience</i> , 2011, 121, 472-476.	1.6	6
785	Tremor in Spinocerebellar Ataxia Type 12. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 76-78.	1.5	6
786	Dystonic Pseudo Foot Drop. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 295-298.	1.5	6
787	Deep Brain Stimulation for Parkinson Disease in Elderly Individuals. <i>JAMA Neurology</i> , 2015, 72, 367.	9.0	6
788	Rapid-Onset Dystonia-Parkinsonism in a Chinese Girl with a De Novo <i>ATP1A3</i> c.2267G>A (p.R756H) Genetic Mutation. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 74-75.	1.5	6
789	Placebos in clinical trials: unravelling a complex phenomenon. <i>Lancet Neurology</i> , The, 2017, 16, 28-29.	10.2	6
790	Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. <i>Cmaj</i> , 2018, 190, E50-E52.	2.0	6
791	Neurostimulation for Functional Neurological Disorder: Evaluating Longitudinal Neurophysiology. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 561-563.	1.5	6
792	Deep brain stimulation in status dystonicus caused by anti-NMDA receptor encephalitis. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 255-257.	2.2	6

#	ARTICLE	IF	CITATIONS
793	The Waiting Room: neurological observations made outside the movement disorder specialist's consulting office. <i>Practical Neurology</i> , 2019, 19, 295-301.	1.1	6
794	Successful pallidotomy for post-hyperglycemic hemichorea-ballism. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 228-230.	2.2	6
795	Beta-propeller protein associated neurodegeneration (BPAN); the first report of three patients from Iran with de novo novel mutations. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 231-233.	2.2	6
796	Twinkle-associated familial parkinsonism with Lewy pathology. <i>Neurology</i> , 2020, 95, 644-647.	1.1	6
797	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 44-45.	2.2	6
798	Movement Disorders: Diagnosis and Assessment. , 2008, , 293-325.		6
799	Corticobasal ganglionic degeneration and/or frontotemporal dementia?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 705-705.	1.9	6
800	Parkinson's disease in 1984: an update. <i>Cmaj</i> , 1984, 131, 1031-7.	0.1	6
801	Update on the treatment of tics. <i>Advances in Neurology</i> , 2001, 85, 355-62.	0.8	6
802	Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 522-529.	1.5	6
803	Insulin-induced hypoglycaemia does not abolish chorea.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1982, 45, 936-937.	1.9	5
804	Treatment of Early Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, S39-S44.	0.5	5
805	Reporting clinical trials. <i>Neurology</i> , 2002, 58, 347-348.	1.1	5
806	Reporting clinical trials: Full access to all the data. <i>Movement Disorders</i> , 2002, 17, 3-4.	3.9	5
807	Title is missing!. <i>Current Opinion in Neurology</i> , 2003, 16, 523-527.	3.6	5
808	Reply: Parkinson's disease, DBS and suicide: a role for serotonin?. <i>Brain</i> , 2009, 132, e127-e127.	7.6	5
809	Tremor-Dominant Pantothenate Kinase-associated Neurodegeneration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 772-774.	1.5	5
810	Tracking the course of prodromal Parkinson's disease. <i>Brain</i> , 2017, 140, 259-262.	7.6	5

#	ARTICLE	IF	CITATIONS
811	Brain tissue pulsatility is related to clinical features of Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018, 20, 222-227.	2.7	5
812	[ <sup>18</sup> F]AV $\beta$ 1451 binding and postmortem pathology of CBD. <i>Movement Disorders</i> , 2018, 33, 1360-1361.	3.9	5
813	Tongue Protrusion Dystonia in Pantothenate Kinase-Associated Neurodegeneration. <i>Pediatric Neurology</i> , 2020, 103, 76-78.	2.1	5
814	A Distinct EEG Marker of Celiac Disease-Related Cortical Myoclonus. <i>Movement Disorders</i> , 2021, 36, 999-1005.	3.9	5
815	Axial Impairment Following Deep Brain Stimulation in Parkinson's Disease: A Surgicogenomic Approach. <i>Journal of Parkinson's Disease</i> , 2022, 12, 117-128.	2.8	5
816	Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial. <i>Movement Disorders</i> , 2022, , .	3.9	5
817	<i>DYT4</i> ( <i>DYT4</i> Dystonia): Clinical Anthology of 11 Cases and Systematized Review. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 659-675.	1.5	5
818	Sudden confusion with levodopa withdrawal. <i>Movement Disorders</i> , 1987, 2, 223-223.	3.9	4
819	What is it? Case 1, 1987: Unusual tremors, bradykinesia, and cerebral lucencies. <i>Movement Disorders</i> , 1987, 2, 321-338.	3.9	4
820	Case 1, 1991: A severe and fatal systemic illness first presenting with a movement disorder. <i>Movement Disorders</i> , 1991, 6, 362-370.	3.9	4
821	Essential palatal tremor. <i>Movement Disorders</i> , 2001, 16, 1202-1203.	3.9	4
822	Reporting clinical trials: full access to all the data. <i>European Journal of Neurology</i> , 2002, 9, 123-124.	3.3	4
823	Rapidly progressive behavioral changes and parkinsonism in a 68-year-old man. <i>Movement Disorders</i> , 2004, 19, 534-543.	3.9	4
824	Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 277-286.	0.5	4
825	Stem cell therapy for Parkinson's disease. <i>Annals of Neurology</i> , 2012, 71, 283-283.	5.3	4
826	Acute akathisia. , 0, , 3-19.		4
827	Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. <i>Biomarkers in Medicine</i> , 2015, 9, 89-97.	1.4	4
828	Progression of neuropsychiatric and cognitive features due to exons 2 to 5 deletion in the epsilon-sarcoglycan gene: a case report. <i>Neurocase</i> , 2016, 22, 215-219.	0.6	4

#	ARTICLE	IF	CITATIONS
829	A 21-Year Retrospective Study of the Toronto Western Hospital Deep Brain Stimulation Cohort. <i>Movement Disorders</i> , 2018, 33, 850-852.	3.9	4
830	Comment on "Is it Useful to Classify PSP and CBD as Different Disorders?". <i>Movement Disorders Clinical Practice</i> , 2018, 5, 564-565.	1.5	4
831	Isolated Abdominal Motor Seizures of Mesial Parietal Origin: Epileptic Belly Dancing?. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 396-399.	1.5	4
832	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1561-1569.	2.8	4
833	<scp>Age-Related</scp> Parkinsonian Signs in Microdeletion 22q11.2. <i>Movement Disorders</i> , 2020, 35, 1239-1245.	3.9	4
834	Preferences for Communication About End-of-Life Care in Atypical Parkinsonism. <i>Movement Disorders</i> , 2021, 36, 2116-2125.	3.9	4
835	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 1964-1967.	3.9	4
836	Spinocerebellar Ataxia 40: Another Etiology Underlying Essential Tremor Syndrome. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 944-946.	1.5	4
837	The second family affected with a PRDM8-related disease. <i>Neurological Sciences</i> , 2022, 43, 3847-3855.	1.9	4
838	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases. <i>GeroScience</i> , 2022, 44, 1575-1598.	4.6	4
839	The Interaction between <scp><i>HLA-DRB1</i></scp> and Smoking in Parkinson's Disease Revisited. <i>Movement Disorders</i> , 2022, 37, 1929-1937.	3.9	4
840	Potential benefits of dopamine striatal implant. <i>Annals of Neurology</i> , 1990, 27, 109-110.	5.3	3
841	CQA 206-291 in Parkinson's Disease: An Acute Single Escalating Dosage Study. <i>Canadian Journal of Neurological Sciences</i> , 1990, 17, 416-419.	0.5	3
842	Effect of GPi pallidotomy on neuropsychological function in Parkinson's Disease. <i>Archives of Clinical Neuropsychology</i> , 1997, 12, 419-419.	0.5	3
843	Neonatal Ablation of the Nigrostriatal Dopamine Pathway Does Not Influence Limb Development in Rats. <i>Experimental Neurology</i> , 2002, 177, 547-556.	4.1	3
844	Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 252-252.	3.9	3
845	Deep brain stimulation for dystonia. <i>Movement Disorders</i> , 2011, 26, S3-4.	3.9	3
846	Hemiballismâ€“Hemichorea. , 2013, , 151-161.		3



#	ARTICLE	IF	CITATIONS
847	Efficacy and safety of T2000 in older patients with essential tremor. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 485-486.	2.2	3
848	Placebo effect of medication cost in Parkinson disease: A randomized double-blind study. <i>Neurology</i> , 2015, 85, 742-743.	1.1	3
849	Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 447-448.	0.5	3
850	Will New Genetic Techniques Like Exome Sequencing Obviate the Need for Clinical Expertise? No. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 39-41.	1.5	3
851	Infantile-onset hand dystonia with intellectual disability. <i>Neurology</i> , 2018, 90, 333-335.	1.1	3
852	Smoldering Multiple Myeloma Associated Leukoencephalopathy Presenting with Holmes Tremor, Ataxia, and Pyramidal Syndrome. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 433-435.	1.5	3
853	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. <i>Movement Disorders</i> , 2018, 33, 1195-1203.	3.9	3
854	Single-pulse subthalamic deep brain stimulation reduces premotor-motor facilitation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 224-227.	2.2	3
855	Interhemispheric pathways in agenesis of the corpus callosum and Parkinson's disease. <i>Brain Stimulation</i> , 2020, 13, 360-362.	1.6	3
856	Late-Onset Mitochondrial Membrane Protein-Associated Neurodegeneration With Extensive Brain Iron Deposition. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 120-121.	1.5	3
857	Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1047-1055.	2.8	3
858	Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 171-177.	3.9	3
859	Bilingualism in Parkinson's disease: Relationship to cognition and quality of life. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021, 43, 199-212.	1.3	3
860	Multimodal Longitudinal Neurophysiological Investigations in Dopa-Responsive Dystonia. <i>Movement Disorders</i> , 2021, 36, 1986-1987.	3.9	3
861	A Novel COVID Era-Related Oromandibular Dyskinesia: Surgical Mask-Induced Dyskinesia?. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 470-471.	0.5	3
862	Longitudinal evaluations of somatosensory-motor inhibition in Dopa-responsive dystonia. <i>Parkinsonism and Related Disorders</i> , 2022, 95, 40-46.	2.2	3
863	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 816465.	2.6	3
864	Targeted copy number variant identification across the neurodegenerative disease spectrum. <i>Molecular Genetics &amp; Genomic Medicine</i> , 0, , .	1.2	3

#	ARTICLE	IF	CITATIONS
865	Iris pigmentation in idiopathic dystonia. <i>Annals of Neurology</i> , 1982, 12, 585-586.	5.3	2
866	Hemiballism-Hemichorea. <i>Archives of Neurology</i> , 1990, 47, 619-619.	4.5	2
867	Corticobasal degeneration syndrome with basal ganglia calcification: Fahr's disease as a corticobasal look-alike?. <i>Movement Disorders</i> , 2003, 18, 351-352.	3.9	2
868	Structural and functional magnetic resonance imaging in neurodegenerative diseases. , 2005, , 253-289.		2
869	Multiple system atrophy. , 2005, , 623-662.		2
870	Clinical Practice Regarding Dopamine-Agonist Use and Driving in Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2007, 34, 438-442.	0.5	2
871	Polymyoclonus, Laryngospasm, and Cerebellar Ataxia Associated With Adenocarcinoma and Multiple Neural Cation Channel Autoantibodies. <i>Archives of Neurology</i> , 2009, 66, 1285-7.	4.5	2
872	Reconciling Braak's model of Parkinson's disease with a prion-like spread of alpha synuclein pathology. <i>Basal Ganglia</i> , 2012, 2, 167-170.	0.3	2
873	Extreme task specificity: Is it dystonia or another form of motor programming abnormality?. <i>Movement Disorders</i> , 2012, 27, 1202-1203.	3.9	2
874	In pursuit of prodromal Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 27-28.	10.2	2
875	On the long-term outcome of orthostatic tremor. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1290-1291.	2.2	2
876	Levodopa and Parkinson Disease—Myths Revisited—Reply. <i>JAMA Neurology</i> , 2017, 74, 1270.	9.0	2
877	Is there even such a thing as "idiopathic normal pressure hydrocephalus"? <i>Annals of Neurology</i> , 2017, 82, 1032-1032.	5.3	2
878	Amantadine for Gait Dysfunction in Pantothenate Kinase-Associated Neurodegeneration. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 782-784.	0.5	2
879	Jumping to overcome freezing of gait while turning in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 349-351.	2.2	2
880	Diffuse Brain Calcification, a Novel SLC20A2 Variant, Vertical Supranuclear Gaze Palsy, and Systemic Lupus Erythematosus. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 403-405.	1.5	2
881	Expert comment to: Novel Xp21.1 deletion associated with unusual features in large McLeod syndrome kindred. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 133-134.	2.2	2
882	Initiating pharmacotherapy in early Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 643-644.	10.2	2

#	ARTICLE	IF	CITATIONS
883	Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2020, 94, 144-145.	1.1	2
884	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency? Response from the authors. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 80.	2.2	2
885	Is clinical assessment enough? Moving towards early differentiation of neurodegenerative parkinsonisms. <i>Brain</i> , 2021, 144, 1040-1042.	7.6	2
886	Reply to: "The Logic and Pitfalls of Parkinson's as Brain Versus Body First Subtypes" <i>Movement Disorders</i> , 2021, 36, 786-787.	3.9	2
887	Dream Enactment Behavior Disorder Associated with Pallido-Nigro-Lusian Degeneration and Tau Proteinopathy. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 594-599.	1.5	2
888	Neuropsychiatric disorders and COVID-19. <i>Lancet Psychiatry</i> , 2021, 8, 564-565.	7.4	2
889	Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease. <i>Clinical Autonomic Research</i> , 2021, 31, 729-736.	2.5	2
890	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 1: Genetic Disorders. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 297-310.	1.5	2
891	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 311-325.	1.5	2
892	Parkinsonism in corticobasal degeneration. <i>Advances in Neurology</i> , 2000, 82, 83-9.	0.8	2
893	Case of a Man with Hemichorea and Behavioral Changes: "A Red Herring" <i>Movement Disorders Clinical Practice</i> , 2022, 9, 501-507.	1.5	2
894	Vitamins B6 and B12, levodopa, and their complex interactions in patients with Parkinson's disease. <i>Brain</i> , 0, , .	7.6	2
895	Letters to the editor. <i>Movement Disorders</i> , 1996, 11, 342-345.	3.9	1
896	69-Year-old man with gait disturbance and parkinsonism. <i>Movement Disorders</i> , 2001, 16, 548-561.	3.9	1
897	<i>Movement Disorders: an Overview.</i> , 0, , 3-19.		1
898	Selected genetically engineered models relevant to human neurodegenerative disease. , 2005, , 176-195.		1
899	Therapy of the Motor Features of Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010, 34, 252-272.	0.1	1
900	Measuring quality of life in progressive supranuclear palsy. , 2011, , 52-59.		1

#	ARTICLE	IF	CITATIONS
901	Crossing the borders between neurology and psychiatry in functional neurological disorders. <i>Movement Disorders</i> , 2011, 26, 1373-1374.	3.9	1
902	Commentary. <i>Movement Disorders</i> , 2013, 28, 1806-1807.	3.9	1
903	Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. <i>Neurology</i> , 2013, 81, 1181-1181.	1.1	1
904	Reply to: Gray et al. <i>Movement Disorders</i> , 2014, 29, 1225-1226.	3.9	1
905	Reply: Dystonia after severe head injuries. <i>Movement Disorders</i> , 2014, 29, 578-579.	3.9	1
906	Focal Predominant Forms of Posthypoxic Action Myoclonus. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 417-420.	1.5	1
907	Augmented Restless Legs Syndrome with Marked Hyperkinesias and Impulsive/Compulsive Behaviors. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 412-414.	1.5	1
908	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 53-58.	1.5	1
909	Reply letter to Jinnah "Locus pocus" and Albanese "Complex dystonia is not a category in the new 2013 consensus classification": Necessary evolution, no magic!. <i>Movement Disorders</i> , 2016, 31, 1760-1762.	3.9	1
910	CLIPPERS: A Treatable Cause of Spastic Ataxia. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 212-214.	1.5	1
911	Cortical GABAergic dysfunction underlying abnormal hand movements in ARX mutation. <i>Clinical Neurophysiology</i> , 2019, 130, 1750-1751.	1.5	1
912	Gelastic Cataplexy in Niemann Pick Type C. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 498-499.	1.5	1
913	Isolated lingual myoclonus in an HIV patient. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 241-244.	2.2	1
914	Recurrent neurologic symptoms complicating venom immunotherapy in a patient with systemic mastocytosis and severe Hymenoptera allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 780-782.	3.8	1
915	Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders. <i>Clinical Neurophysiology Practice</i> , 2021, 6, 103-108.	1.4	1
916	Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-5.	0.5	1
917	Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1125-1125.	3.9	1
918	Teaching Video Neurolmage: "Weighing" in on an Unusual Tremor. <i>Neurology</i> , 2021, 97, e970-e971.	1.1	1

#	ARTICLE	IF	CITATIONS
919	Exacerbation of Stiff Person Syndrome by Selective Serotonin Reuptake Inhibitors. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 772-774.	1.5	1
920	Periodic Alternating Gaze Deviation Due to Paraneoplastic Cerebellar Degeneration. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 791-793.	1.5	1
921	Irreversible extreme freezing of gait after dopamine agonist withdrawal. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04712.	0.5	1
922	The Discovery of $\alpha$ -Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1189-1193.	1.5	1
923	Commentary: Is Tardive Dyskinesia Disappearing?. , 0, , 302-310.		1
924	Rating Scales for Movement Disorders. , 0, , 20-29.		1
925	Identical twins with progressive kyphoscoliosis and ophthalmoplegia. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 119-122.	2.2	1
926	Oculogyric Crisis Phenotype of Levodopa-Induced Ocular Dyskinesia. <i>Movement Disorders Clinical Practice</i> , 0, , .	1.5	1
927	The Role of Insular Cortex in Gut Inflammation Memory: What Does It Mean for Parkinson's Disease?. <i>Movement Disorders</i> , 2022, 37, 700-701.	3.9	1
928	Genomic study of a large family with complex neurological phenotype including hearing loss, imbalance and action tremor. <i>Neurobiology of Aging</i> , 2022, 113, 137-142.	3.1	1
929	Pallidal neuronal activity in multiple system atrophy type P and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 101, 15-17.	2.2	1
930	Recommendations for Virtual Administration of the <sc>PSP</sc> Rating Scale. <i>Movement Disorders</i> , 2022, 37, 1960-1961.	3.9	1
931	Plioplys replies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1988, 51, 1010-1010.	1.9	0
932	What is it? Case 1, 1992: Progressive gait deterioration, peripheral neuropathy, optic atrophy, bradykinesia, and dystonia in a young girl. <i>Movement Disorders</i> , 1992, 7, 373-379.	3.9	0
933	Reporting clinical trials: full access to all the data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 143-143.	1.9	0
934	Reporting clinical trials: Full access to all the data. <i>Muscle and Nerve</i> , 2002, 25, 133-134.	2.2	0
935	Normalization of voice in spasmodic dysphonia during transient global amnesia. <i>Movement Disorders</i> , 2005, 20, 1228-1229.	3.9	0
936	Corticobasal degeneration. , 2005, , 682-696.		0

#	ARTICLE	IF	CITATIONS
937	Neurophysiology of Parkinson's disease, levodopa-induced dyskinesias, dystonia, Huntington's disease and myoclonus. , 2005, , 227-250.		0
938	Current and potential treatments of Parkinson's disease. , 2005, , 612-622.		0
939	Can visual hallucinations be used as a diagnostic factor in Parkinson's disease?. Nature Clinical Practice Neurology, 2006, 2, 246-247.	2.5	0
940	An update on movement disorders: exciting developments but new obstacles. Current Opinion in Neurology, 2007, 20, 432-433.	3.6	0
941	Reply: The variability of levodopa response in Parkinson's disease: Is sensitization reversible?. Movement Disorders, 2008, 23, 925-925.	3.9	0
942	Treatment of Motor Complications in Advanced Parkinson's Disease. , 2008, , 71-90.		0
943	PATIENT MANAGEMENT PROBLEM. CONTINUUM Lifelong Learning in Neurology, 2008, 14, 182-193.	0.8	0
944	Dopamine Agonists vs Levodopa in Impulse Control Disordersâ€”Reply. Archives of Neurology, 2011, 68, 544.	4.5	0
945	Reply to Drs. Kurlan, Fasano, and Evans: A clinically useful definition of stereotypies. Movement Disorders, 2013, 28, 405-406.	3.9	0
946	Reply to letter: multiple system atrophy-parkinsonism with slow progression and prolonged survival: A diagnostic catch. Movement Disorders, 2013, 28, 408-408.	3.9	0
947	The Saskatchewan Movement Disorders Program: Commitment Pays Off. Canadian Journal of Neurological Sciences, 2015, 42, 70-71.	0.5	0
948	Restless Genital Syndromeâ€”Reply. JAMA Neurology, 2015, 72, 479.	9.0	0
949	Lessons learned: neuroprotective trials in Parkinson's disease. , 0, , 265-279.		0
950	The Clinical Spectrum of Functional/Psychogenic Dystonia. , 0, , 217-223.		0
951	Dancing Dorsal Quadrilateralsâ€”Organic or Functional?â€”Reply. JAMA Neurology, 2019, 76, 985.	9.0	0
952	Reply to â€œStudying reproducibility of data-driven Parkinson's disease subtypesâ€” Parkinsonism and Related Disorders, 2019, 66, 245-246.	2.2	0
953	Tremor with congenital mirror movements: evidence of involvement of the primary motor cortex in tremor. European Journal of Neurology, 2019, 26, e66-e67.	3.3	0
954	Preface to the Video Challenge Supplement for Movement Disorders Clinical Practice. Movement Disorders Clinical Practice, 2020, 7, S53-S54.	1.5	0

#	ARTICLE	IF	CITATIONS
955	“Opening” New Insights Into <i>LRRK2</i> Conformation and the Microtubule. <i>Movement Disorders</i> , 2020, 35, 2162-2163.	3.9	0
956	Abnormal brain structure mediates the association between ApoE4 and slow gait among patients with pathological cognitive impairment: Results from the Ontario Neurodegenerative Research Initiative. <i>Alzheimer's and Dementia</i> , 2020, 16, e044540.	0.8	0
957	Phenotype differences between corticobasal syndrome and progressive supranuclear palsy with and without Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e046071.	0.8	0
958	Heart rate variability biomarkers of leucine-rich repeat kinase 2-associated Parkinson's disease. , 2020, , .		0
959	Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia. <i>Movement Disorders</i> , 2021, 36, 265-266.	3.9	0
960	Hyperglycemic hemichorea presenting with normal MRI and striatal hyperdensity on CT. <i>Neurological Sciences</i> , 2021, 42, 4341-4343.	1.9	0
961	Sleepiness and Sleep Attacks in Parkinson's Disease. <i>Advances in Behavioral Biology</i> , 2002, , 385-390.	0.2	0
962	Acute Effects of Levodopa and Pallidotomy on Bimanual Repetitive Arm Movements in Patients with Parkinson's Disease. <i>Advances in Behavioral Biology</i> , 2002, , 43-50.	0.2	0
963	Psychogenic Dystonia. <i>Medical Psychiatry</i> , 2006, , 277-288.	0.2	0
964	Surgery for Movement Disorders: An Overview. , 2009, , 1443-1466.		0
965	Other Movement Disorders. , 2012, , 2333-2342.		0
966	Psychogenic dystonia. , 2012, , 307-319.		0
967	Isolated Ear Clicks with Partial Voluntary Control. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, 55.	2.0	0
968	Contemporary assessment and pharmacotherapy of Tourette syndrome. <i>Neurotherapeutics</i> , 2006, 3, 192-206.	4.4	0
969	Differences in Drug Pharmacokinetics and Motor Fluctuation in DYT-1. <i>Canadian Journal of Neurological Sciences</i> , 2021, 48, 734-736.	0.5	0
970	Teaching Video NeuroImage: Unilateral Myorhythmia in a Patient With a Midbrain-Diencephalic Junction Cavernous Malformation. <i>Neurology</i> , 2022, 98, .	1.1	0
971	Teaching Video NeuroImage: Reversible Caudate Changes in a Patient With Post-Pump Chorea. <i>Neurology</i> , 2022, 98, 731-732.	1.1	0
972	Differential cognitive correlates of tau and neurofilament light chain in cerebrospinal fluid of frontotemporal lobar degeneration patients with and without Alzheimer's markers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
973	Evolution of Parkinson's Disease and Treatment Requirements: What New Treatments are Needed and the Role of Striatal Grafting. , 2006, , 50-64.		0
974	Patient Selection for Movement Disorders Surgery. , 0, , 53-68.		0
975	Posteroventral medial pallidotomy in Parkinson's disease. Journal of Neurology, 1999, 246, s028-s041.	3.6	0
976	Periodic Limb Movements While Awake (PLMA) as a manifestation of Wearingâ€œOff in Parkinson's Disease: A Case Series and Review of the Literature. Movement Disorders Clinical Practice, 0, , .	1.5	0
977	Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease. JAMA Neurology, 2022, 79, 726.	9.0	0